The Chaperone Potential of Protein Nanoparticles by GARDINER, ALICE,REBECCA
Durham E-Theses
The Chaperone Potential of Protein Nanoparticles
GARDINER, ALICE,REBECCA
How to cite:
GARDINER, ALICE,REBECCA (2010) The Chaperone Potential of Protein Nanoparticles, Durham
theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/3194/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Oﬃce, Durham University, University Oﬃce, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
 1 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1. Nanotechnology 
 
In recent years, nanotechnology has risen to the forefront of scientific research, thanks to 
the unique advantages of working on the nanoscale.  Nanomaterials are defined as 
substances smaller than 100nm in at least one dimension (Roco 2003), and the term covers 
a great many and a large variety of products across many disciplines, although I will be 
focusing only on their applications within biology.   
 Nanoparticles have been used as vectors for the transportation of drugs, genes and 
antigens for immunisation. In addition, they are being used for screening as a diagnostic 
tool, and are becoming increasingly important in the treatment of cancer.  Self-assembly is 
a feature of some nanoparticles that are of particular importance to this project. 
    
 
1.1.1. Drug delivery   
 
For many of the problems faced within the field of drug delivery, nanoparticles appear to 
offer a solution.  Their size, pharmacokinetic properties, and potential for surface 
modification are making them an increasingly appealing prospect within the 
pharmaceutical industry; consequently research is being conducted on a great number of 
different nanoparticulate drug delivery systems. 
Due to their size, nanoparticles have a very high surface area to volume ratio 
compared with that of traditional drugs, which yields a greater bioavailability, i.e. a higher 
proportion of the initially administered drug reaches the blood (Emerich and Thanos 
2006), hence providing a more effective treatment.  Furthermore, drugs that need to pass 
through usual problem areas such as the pulmonary system and tight epithelial cell 
junctions in the skin typically have to be specially designed, but nanoparticles’ size means 
passage through these junctions is not problematic (Emerich and Thanos 2006).  When 
PEGylated (see below), they can also pass through the blood brain barrier (BBB) by 
binding to the receptor B1 (Kairemo, Erba et al. 2008).  Designing drugs able to cross the 
BBB is traditionally very difficult to do, yet is a prerequisite for their being able to treat 
diseases such as brain cancer and Alzheimer's disease (Chopra, Gulati et al. 2008). 
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  Perhaps the most important advantage that nanoparticles provide is the scope for 
surface modification.  ‘Conventional’ nanoparticles, with unmodified surfaces, are quickly 
cleared from the blood (Grislain, Couvreur et al. 1983) due to an immunogenic process 
called opsonisation.  Blood opsonic factors, for example antibodies or components of the 
complement system, bind to the surface of the particle, targeting it for clearance by 
phagocytosis.  Traditional drugs also have to be carefully selected and tested to ensure that 
this does not present a problem for their mode of action.  So-called ‘second generation’ 
nanoparticles however, are modified to protect against opsonisation, the most common 
method involves coating the surface in polyethylene glycol (PEG). PEG is a hydrophilic 
co-polymer which resists opsonisation by sterically hindering opsonins from binding to 
the surface, thus maximising activity by prolonging the time of the drug in the blood 
(Boerman, Oyen et al. 1997); this process is known as PEGylation.  Another application 
of nanoparticle surface modification is targeting the drug to a particular cell type, for 
example epithelial cells, based on the surface profile of the cell (reviewed in (Kim and 
Dobson 2009)).  Consequently, the drug accumulates in the targeted cells, and so is at a 
high concentration where it is required.  This also helps it avoid macrophages (Moghimi, 
Hunter et al. 2001), prevents drug wastage and reduces side effects, as the drug only 
affects infected tissues.  This is used widely in cancer research (see section 1.1.4. 
nanoparticles in cancer). 
Pharmacokinetics is concerned with how the body affects a drug, and is divided 
into four areas: absorption, distribution, metabolism and elimination (ADME).  Therefore, 
the most efficient drugs are those which are well absorbed into the blood, distributed to 
the places where it is needed, and not metabolised or eliminated too quickly (Zolnik and 
Sadrieh 2009).  All the advantages of using nanoparticles in drug delivery that have been 
discussed so far highlight the optimal ADME properties that nanoparticles have the 
potential to provide.   They also provide a means for possible reformulation of molecules 
that were previously thought to be good drug candidates, but were not able to be used due 
to poor pharmacokinetic properties.  These could potentially be redeveloped in 
nanoparticle delivery systems, which would have a very large cost-saving implication for 
the pharmaceutical industry (Emerich and Thanos 2006). 
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There are two main types of nanoparticle used for drug delivery: nanospheres and 
nanocapsules.  Nanospheres are matrix systems, in which the drug is uniformly dispersed 
throughout the particle, whereas nanocapsules are vesicles in which the drug is 
encapsulated by a polymer membrane (Barratt 2003).  Nanoparticles used in drug delivery 
tend to be made of biodegradable polymers or co-polymers, allowing for slow and 
sustained release of the drug at the target site over a long period (Singh and Lillard 2009) 
and subsequently results in no trace of the carrier.   
 
 
1.1.2. Gene Therapy 
 
Gene therapy involves the transport of a gene into the nucleus of a targeted cell.  In 
nanotechnology this can be done by the use of liposomes which are similar to 
nanocapsules differing in that their contents are surrounded by a lipid bi-layer instead of a 
polymer membrane.  The advantage of this is that the liposome can pass through the lipid 
bilayer of the cell, and so remain intact within the cell.  Consequently, the gene can be 
delivered to the nucleus without being damaged by exposure to the cell cytosol (Emerich 
and Thanos 2006).  Several examples of this technology have been published (Liu, Zern et 
al. 2003) (Zhang, Schlachetzki et al. 2003).  The latter of these is an example of targeted 
gene therapy: the surface of an immunoliposome containing the plasmid was PEGylated 
and subsequently linked to an antibody for the human insulin receptor (HIRMAb).  This 
targeted the gene to the brain of a monkey, as the antibody allowed it to pass through the 
BBB via transcytosis and then across the neuronal plasma membrane by endocytosis. 
Another possible method of delivering genes is again to use polymeric 
nanospheres, similar to that used in drug delivery. The gene can be delivered into the 
cytoplasm, but it has not yet been established how to use this method to transport the gene 
straight into the nucleus.  However, despite this, the method has had some successes 
(Cohen-Sacks, Najajreh et al. 2002) (Perez, Sanchez et al. 2001).   
A third type of nanoparticle used in gene delivery is dendritic or hyperbranched 
polymers. These conjugate with the DNA by ionic interactions between the negative 
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phosphate backbone of the DNA and the positive polymer of the nanoparticle (reviewed in 
(Gillies and Frechet 2005)). 
 
 
1.1.3. Screening and diagnostics 
 
Molecular screening is used as a diagnostic tool to identify disease, for example in 
screening for cancer cells.  There are two elements of a molecular screening system: 
recognition and signal transduction. Therefore both of these components must be efficient 
in order for the system to be successful.  Nanoparticles are increasingly being 
implemented as a novel way to amplify the efficacy of screening systems, making use of 
the unique optical, electronic and magnetic properties that their cores can provide.  They 
can be used to detect metal ions, proteins, nucleic acids and microorganisms (Agasti, Rana 
et al. 2010).  One of the first types of nanoparticles used in this field was quantum dots 
(QDs): nanocrystals consisting of a CdSe core with a ZnS shell.  QDs are fluorescent 
nanoparticles, which, once excited, fluoresce in a large range of colours, dependent on 
particle size.  They can be functionalised with antibodies or ligands, which when bound to 
their substrate, the molecule being screened for, elicit a signal.  This has improved the 
fluorescent markers used for protein detection:  traditional markers were short lived, but 
the signal of QDs decays very slowly and so they last much longer.  The markers also 
used dyes which ran together, leading to difficulty in discriminating between differently 
stained proteins.  QDs however do not have this problem, and consequently several events 
in a cell can be monitored simultaneously (reviewed in (Medintz, Uyeda et al. 2005)).  
They can also be used in the detection of other molecules, such as nucleic acids and metal 
ions (Agasti, Rana et al. 2010). 
 Another field of nanotechnology used for screening is known as colorimetric 
detection, which employs nanoparticles that change colour when the ligand is bound or 
upon clustering.  Gold particles are often used for this (AuNPS) and can detect many 
substrates, such as harmful heavy metal ions (Huang and Chang 2007), proteins (Otsuka, 
Akiyama et al. 2001) and nucleic acids, where the AuNP is functionalised with a DNA 
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strand so that a complimentary sequence is recognised and elicits a signal (Thaxton, 
Georganopoulou et al. 2006). 
 A final example of the many applications of nanoparticles in this area is a ‘bio-
barcode’ assay.  Similarly to colorimetirc detection, an AuNP is linked to DNA.  The 
target oligonucleotide binds, and this is then ‘sandwiched’ with another AuNP.  A 
magnetic field is used to separate the complex from the target solution, and the DNA is 
detected (Agasti, Rana et al. 2010).  Alternatively a protein or other immunogen can be 
detected if the AuNP is attached to a monoclonal antibody. 
 
 
1.1.4. Nanoparticles in cancer 
 
Cancer research is, of course, a highly important field, and so it is no surprise that it is an 
area in which nanotechnology is being implemented ever more.  Similarly to the rest of 
medical biology, the areas that can most benefit from the use of nanoparticles are drug 
delivery and imaging (Kairemo, Erba et al. 2008).   
 Anticancer drugs, usually more so than other drugs, need to be targeted to the 
tumour site, as they can have adverse effects on normal tissues.  Therefore being able to 
target nanoparticles offers a significant advantage for using them in drug delivery.  There 
are two ways this can happen: passively or actively.  Passive targeting is an option 
because tumour blood vessels have higher permeability than ordinary blood vessels, in 
order for the tumour to get enough nutrients (Ferrara and Gerber 2001).  Consequently, 
providing that the nanoparticle stays in the blood long enough, it will accumulate at the 
tumour site.  However, this method is not always feasible, and does not work for larger 
tumours, in which the vascularisation is poor, and so active targeting can be used instead.  
Cancer cells tend to overexpress some of their surface receptors (Kim and Dobson 2009) 
and this can be exploited: ‘smart’ nanoparticles can be made, displaying a 
receptor/substrate which binds to the complimentary ligand on the cancer cell.  For 
example, folic acid receptors are overexpressed on cancer cells, and so nanoparticles are 
being developed which display folic acid on their surface (Thomas, Majoros et al. 2005).  
Antibodies can also be used, but to avoid provoking an immune response, either only a 
 7 
fragment is used, or a non-binding region is modified with a human region (Kim and 
Dobson 2009). 
 The other area in which nanoparticles can be implemented within cancer research 
is in imaging.  Magnetic resonance imaging (MRI) is a useful technique for indentifying 
tumour tissue.  The tumour must be highlighted with a contrast agent in order to be seen, 
and nanoparticles can be used to do this, for example, a nanoparticle consisting of a 
PEGylated iron centre, which disturbs the magnetic field by containing a magnetic 
moment (Kairemo, Erba et al. 2008).  Another way in which nanoparticles may be used in 
imaging is with ultrasound.  Traditionally, ultrasound uses only the excitation of minute 
gas bubbles, but solid nanoparticles have also been used in addition to the bubbles to 
enhance the image (Liu, Levine et al. 2006).   
Although many of these nanoparticle functions are still being researched and not 
yet in use, hopefully in the future nanoparticles will have a large roll in cancer treatment. 
 
 
1.1.5. Antigen delivery and immunisation  
 
Vaccination can be carried out using live attenuated virus strains, killed viruses or 
deactivated toxins.  However, all of these methods have disadvantages, such as attenuated 
viruses reverting back to a dangerous form, or toxins producing a poor immunogenic 
response, in which case it is often better to use the viral antigen to provoke an immune 
response.  The antigen by itself would have a poor level of immunogenicity, therefore it 
must be linked to an adjuvant, which promotes a stronger immune response.  It must also 
have a carrier: this can be a nanoparticle. Antigens can be delivered, like drugs, in 
nanocapsules or nanospheres (Lutsiak, Robinson et al. 2002).  However, they can also be 
delivered in a range of other vectors, such as non-replicating viruses, virosomes and 
calcium phosphate nanoparticles (reviewed in (Peek, Middaugh et al. 2008))     
 Antigens can also be delivered as part of the nanoparticle itself, as shown by the 
Burkhard group.  Instead of being a vector, in this case, the nanoparticles’ activity is 
intrinsic to their design.  They were first invented in 2006, when a monomer was 
computationally designed with oligermerisation domains that would lead to efficient self-  
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A. 
B. C. 
Figure 1.1 Composition of the peptide nanoparticles that I will be making.   
A. Amino acid sequence of the monomer, excluding his-tag region.  Green represents 
the pentameric coiled-coil COMP domain: blue represents the trimeric coiled-coil 
domain.  
B. The arrangement and symmetry elements of the monomer, with the linker region 
shown in turquoise. 
C.  Computer model of assembled ‘empty’ nanoparticle, composed of 60 monomers. 
D.  DNA and corresponding amino acid sequence of the peptide in ‘empty’ nanoparticle, 
which will be displayed on the surface.  
Adapted from (Raman, Machaidze et al. 2006)  
D. 
GGGGGGGCAGTGGAGATCCGCCACCTCCCAACCCGAATGACCCACCGCCTCCGAATCCGAACGATTGA 
R  G  G  S  G  D  P  P  P  P  N  P  N  D  P  P  P  P  N  P  N  D 
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assembly (see section 1.1.6. Self-assembly of nanoparticles) into spherical nanoparticles 
of roughly 16nm in diameter (Raman, Machaidze et al. 2006).  The monomer has two 
domains: a pentameric coiled-coil COMP (Cartilage Oligomerisation Matrix Protein) 
domain, and a specially designed trimeric coiled-coil domain, joined by a linker region.  
As shown in Figure 1.1, the monomers self-assemble into a 60-mer with a very high level 
of symmetry (dodecahedral).  The monomer was then engineered to contain a third region, 
a peptide (Figure 1.1 D) which can be replaced by any other peptide of choice.  Once 
assembled, this region is displayed repetitively on the surface of the nanoparticle.  
Consequently these nanoparticles were designed as a very efficient antigen presentation 
system, as not only is the antigen displayed 60 times on one molecule, its high level of 
symmetry and repetitive antigen display system causes it to resemble a virus and therefore 
elicit an increased immune response relative to other antigens (Baschong, Hasler et al. 
2003).  The Burkhard group have so far published two uses for their nanoparticles.  The 
first was to create a vaccine for the SARS virus (which had previously proven difficult), 
by displaying a region of the B-cell epitope on the surface of the nanoparticle (Pimentel, 
Yan et al. 2009).  The second use was to create actin antibodies, which, due to its highly 
conserved nature, has again posed a problem in the past.  They used a region of actin 
called the ‘hydrophobic loop’ which is buried in filamentous actin, but exposed in soluble 
actin (Schroeder, Graff et al. 2009).  For the first time antibodies were made able to detect 
specifically the levels of soluble actin in the cell.  This is called a neo-epitope.   
 
 
1.1.6. Self-assembly of nanoparticles 
 
Historically in nanotechnology, photolithography (using light to etch onto surfaces) has 
been used to create two-dimensional nanostructures (Rajagopal and Schneider 2004).  
This is known as a ‘top down’ approach.  However, an alternative, is molecular self-
assembly, defined as the ‘spontaneous diffusion and specific association of molecules 
dictated by non-covalent interactions’ (Rajagopal and Schneider 2004).  In nature, the 
self-assembling of identical subunits to produce bigger structures (a ‘bottom up’ 
approach) is a process widely observable.  Examples include some components of the 
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cytoskeleton, bacterial extracellular and intracellular protein layers and viral capsids 
(Papapostolou and Howorka 2009).  First proposed by Richard Feynman in 1959, 
molecular self-assembly based on nature has proven to be an alternative method in 
synthetic biology for creating three-dimensional bionanostructures (Feynman 1960).  Self-
assembly offers several advantages.  The first is that, as the end product is dictated by the 
monomers used to create it, it is very easy to adapt or alter the nanoparticle’s final 
structure by simple engineering of the monomer.  It also makes the assembly reliable and 
replicable, as it is governed by molecular interactions and there is no scope for human 
error.  Additionally, the use of enzymes is usually not needed, as all of the assembly 
information is encoded within the monomer.  Consequently, using self-assembly is a very 
attractive prospect for making nanoparticles, if the material allows.  
 
 
1.1.7. The nanoparticles used in this project 
 
This project will make use of the nanoparticles created by the Burkhard group (see section 
1.1.5. Antigen delivery and immunisation and Figure 1.1).  As previously discussed, they 
were originally designed to be a very efficient antigen display system; however, this will 
not be their function in this project.  They were also designed to self-assemble, which, as 
explained (see section 1.1.6. Self-assembly of nanoparticles), is very advantageous, as it 
makes them reproducible, adaptable, and much easer to produce.  
 
 
1.2. Protein chaperones  
 
 
Protein chaperones are proteins that mediate the folding, refolding, and prevention of 
aggregation of other proteins.  Unfolded, misfolded or denatured (non-native) proteins 
have exposed hydrophobic regions which, if left exposed, interact with other non-native 
proteins, leading to protein aggregation.  This is usually irreversible and damaging to the 
cell.  Protein chaperones have their own hydrophobic domains, which they use to bind to 
these vulnerable exposed proteins and so prevent aggregation from occurring.  Most 
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protein chaperones are expressed constitutively, but for some their expression increases in 
times of physical stress, for example increased temperature.  These proteins are called heat 
shock proteins (HSPs), whereas constitutive proteins are known as HSCs.  
There are four classes of protein chaperones native to humans, each with distinct 
mechanisms of chaperoning and with varying functions.  The chaperonins chaperone the 
folding of newly translated proteins, as well as the refolding of misfolded proteins.  They 
do this by enclosing the non-native protein within one of two chambers, where the 
hydrolysis of ATP leads to proper folding.  The HSP70s, however, largely chaperone by 
protecting and folding peptides during translation.  They function, with the aid of a co-
chaperone, by binding to a hydrophobic site on the peptides.  Again, ATP is required for 
folding.  Similarly, the HSP90s require both co-chaperones (sometimes HSP70 itself) and 
ATP to function, but they play a more regulatory role within the cell, and thus 
chaperoning occurs slowly.  They, again, bind to the chain of peptide, but unlike HSP70, 
they have a ‘lid’ region which closes to allow chaperoning.  The last class of chaperone is 
the sHSPs, which do not actively fold non-native proteins, but instead protect them by 
binding to them, before passing them to one of the other chaperones; this is an ATP-
independent process. 
Therefore, it is easy to see that all of the different chaperones work together in a 
cell, and all are required to ensure the proper folding of all proteins (Hartl and Hayer-Hartl 
2002).   
 
 
1.2.1. Chaperonins  
 
The chaperonins are an essential group of protein chaperones, seen in all three organism 
kingdoms, and present in both cytosol and organelles.  They are known to interact with 
10% of newly synthesised cellular proteins (Spiess, Meyer et al. 2004).  Chaperonins carry 
out the final step in the journey from DNA to native protein, following transcription and 
translation, by facilitating the ATP-dependent folding of the completed nascent peptide, if 
not already folded (Horwich, Fenton et al. 2007).  They also function to refold misfolded 
proteins.  In humans there are two classes of chaperonin, divided evolutionarily.  Type I, 
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which has its origins in bacterial cytoplasm, is present in organelles such as mitochondria 
(HSP60).  Type II, originating from archaebacterial cytoplasm, is present in eukaryotic 
cytoplasm (CTT/TRic).  The two types are structurally different, so although they have 
similar activity mechanisms, their encapsulation mechanisms are different (Horwich, 
Fenton et al. 2007).  
 Chaperonins are large (about 800 kDa), complex structures, consisting of two 
rings. Each ring encloses a cavity, which are the active sites.  When the cavity is open, it is 
overwhelmingly hydrophobic, and so binds unfolded or misfolded proteins, as these also 
have exposed hydrophobic regions.  Once a substrate is bound, ATP also binds, causing a 
conformational change of the chaperonin.  The cavity expands, is sealed, and becomes 
largely hydrophilic, promoting the proper folding of the protein.  Subsequently, the ATP is 
hydrolysed to ADP, a new substrate and ATP bind to the opposite cavity, and the ADP 
and folded protein are released (Lucent, England et al. 2009).  If the protein is still not 
folded correctly, it goes through the cycle again.  Even if the protein has to go through this 
process several times, it is still more efficient for the cell than making a new protein 
(Spiess, Meyer et al. 2004).  
 Exactly how the protein is folded within the enclosed cavity is unknown, although 
several mechanisms have been discussed (reviewed in (Lucent, England et al. 2009)).  The 
Anfinsen cage model postulates that the chaperonin does nothing actively to help folding, 
preventing protein aggregation by merely isolating it until it is properly folded (Ellis 
1994).  A second model, the iterative annealing model, suggests that the cavity acts as an 
unfoldase, aiding the folding of a kinetically trapped protein by giving it several attempts 
at folding properly (Weissman, Kashi et al. 1994).  A third model proposes that instead the 
cavity surface acts as a foldase, providing an environment which promotes quicker folding 
than  would be possible were the protein free in the cytosol (Brinker, Pfeifer et al. 2001).  
There is evidence to support all of these models, and in actuality, the mechanism could be 
a mixture of the three, depending on the substrate.  However, as mentioned previously, 
this constitutes just one of several chaperone mechanisms within the cell.  
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1.2.2. The HSP70 system 
  
The HSP70 family of protein chaperones in humans consists of 13 HSP70s and four 
related HSP110s.  HSP70s have two regions: the N-terminal nucleotide binding domain 
(NBD), which has ATPase-activity, and the C-terminal substrate binding domain (SBD) 
(Saibil 2008). They carry out many functions in the cell, often, but not always, in 
conjunction with a co-chaperone, and can be found in the ER (BiP) and mitochondria 
(mtHSP70) as well as the cytosol (Hsc70) (Meimaridou, Gooljar et al. 2009).    
 Like chaperonins, HSP70s function to mediate the ATP-dependent folding of post-
translational nascent peptides, although unlike chaperonins, they can also fold co-
translationally.  Their method of chaperoning, however, is very different; the basic process 
is as follows.  Once bound to ATP, the SBD of the HSP70 binds to a target region of a 
client peptide, for instance, a nascent peptide that has just been translated.  The target 
region consists of roughly five to seven hydrophobic residues flanked by hydrophilic ones; 
a pattern which occurs statistically about every 40 amino acids.  HSP40 acts as a co-
chaperone which presents client peptides to HSP70.  Once bound, ATP is hydrolysed to 
ADP, a process regulated by HSP40, causing HSP70 to clamp onto the peptide in a 
conformational change.  Consequently, the hydrophobic region is no longer exposed, and 
proper folding can occur without the risk of aggregation.  The complex in this form is 
stabilised by Hip, another co-chaperone.  The next step is for Bag, a nucleotide exchange 
factor, to release ADP, along with the folded protein and complete the cycle.  If the 
protein has not been correctly folded, it can undergo multiple cycles until the folding has 
been completed (Meimaridou, Gooljar et al. 2009) (Hartl and Hayer-Hartl 2002) (Witt 
2010).  Again, the exact details of the mechanism of protein folding are unknown.  
 Aside from this housekeeping protein folding function, the HSP70s also have 
many other roles within the cell.  Co-chaperone domains can be seen in modular adaptor 
proteins, which can be found at membranes and at the cytoskeleton.  This localises the 
chaperone activity of HSP70, allowing it to carry out specific cellular functions such as 
protein transport, vesicle secretion and recycling and the regulation of large protein 
complexes in their assembly/disassembly (Young, Barral et al. 2003). 
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1.2.3. The HSP90 system 
 
Less is known about HSP90 than about the other protein chaperones.  Again, it helps with 
protein folding and prevents aggregation, but the substrates of HSP90 are less varied than 
for the other chaperones. HSP90 molecules consist of three regions: the N-domain, which 
contains the ATP binding site and a ‘lid’, a linker region and M domain and the C-
terminal dimerisation domain (Wandinger, Richter et al. 2008).  Like HSP70, HSP90 is 
assisted by a number of co-factors and co-chaperones, and in fact, for some of its 
substrates, is assisted by HSP70 itself.  In these cases, HSP70 stabilises the substrate in a 
conformation which then allows HSP90 to bind to it (Scheufler, Brinker et al. 2000). 
 The details of the process of protein folding are only partially known, but the cycle 
can be outlined.  Once the substrate has passed from HSP70 to HSP90, ATP binds to the 
N-terminal of each monomer and causes the dimer to close and the lids to shut.  The N-
terminals dimerise, forming a stable complex.  The ATP is then hydrolysed by the co-
factor Sba1, allowing the monomers to reopen.  The ADP and substrate are released.  As 
for the other chaperone cycles, if the substrate is not folded after one cycle it may undergo 
more (Wandinger, Richter et al. 2008). 
 HSP90 also plays a regulatory role by inducing conformational change and hence 
activating and stabilising proteins (Jakob, Meyer et al. 1995), and so in turn its activity 
must be regulated.  This regulation occurs in three ways (reviewed in (Wandinger, Richter 
et al. 2008).  Firstly, the hydrolysis of ATP to ADP is very slow, in humans this occurs 
only once every 20 minutes (McLaughlin, Smith et al. 2002).  This is because the 
conformational change resulting in the closure of the complex takes time; however, this 
delay implies a rate limiting step.  Additionally, HSP90 is tightly regulated by all the co-
factors that it requires.  Lastly, regulation occurs by way of post-translational 
modifications, such as phosphorylation: increased temperature leads to higher HSP90 
phosphorylation, which in turn increases activity (Leesmiller and Anderson 1989).  
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1.2.4. The sHSPs 
 
The small heat shock proteins (sHSPs) are a family of protein chaperones, whose subunits 
vary in size between 12 and 40 kDa.  Unlike all the other protein chaperones, they do not 
require ATP for their activity: they protect non-native proteins from aggregation but do 
not actively fold them.  Their function is especially critical in times of physiological 
stress, when they play an important role in preventing irreversible aggregation until 
conditions revert to normal and the protein is passed to an ATP-dependent chaperone for 
folding.  While the structures of the sHSPs vary, they all contain a 100 amino acid 
conserved sequence, the α-crystallin domain (ACD).  It is possession of this domain that 
defines them as sHSPs: it is essential for dimerisation, oligomerisation and chaperone 
ability.  The ACD is always flanked by a variable hydrophobic N-terminal domain, 
responsible for substrate binding and a C-terminal tail containing a conserved sequence, 
which largely lacks secondary structure and hyrodrophobicity.  The protein chains of the 
sHSPs dimerise, and self-assemble to form oligomers: it is thought that there is 
equilibrium between the dimer and the oligomer.  Depending on the specific sHSP 
involved, the oligomers can be homomeric or heteromeric, regular or polydisperse and can 
range in size between 9 and 50 subunits (Mchaourab, Godar et al. 2009) (Sun and MacRae 
2005) (Haslbeck 2002) (Nakamoto and Vigh 2007).  Although these oligomers are 
formed, kinetic studies have shown that they are dynamic and undergo subunit exchange 
(Bova, Ding et al. 1997).  The sHSPs have proved very difficult to crystallise, and 
consequently little is known about their structure or mechanism of chaperoning.  Two 
aspects of sHSPs will be discussed in more detail: structure, using HSP16.5, from the 
hyperthermophilic archaebacterium, Methanococcus jannaschi, and HSP16.9 from wheat, 
as they are the only two which have been crystallised: and chaperoning, largely using αB-
crystallin, as it is the archetypal sHSP and has been the subject of the most research. 
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1.2.4.1. Structure – HSP16.5 and HSP16.9 
 
The structure of HSP16.5 could be determined using crystallography.  The structure is a 
sphere consisting of 24 subunits, all paired into dimers (Kim, Kim et al. 1998).  It has 
three sets of eight subunits (Figure 1.2A) and octahedral symmetry.  The sphere is hollow, 
like the chaperonins, but without an entrance.  The surface has 14 ‘windows’, eight 
trigonal and six square, which are large enough to contain small enzymes and 
polypeptides.  The surface is 22% hydrophobic, although the locations of the N-terminal 
extensions could not be determined from the crystal structure.  
 The structure of HSP16.9, which also forms monodisperse oligomers, is quite 
different (van Montfort, Basha et al. 2001).  It is a eukaryotic sHSP, as opposed to the 
prokaryotic HSP16.5.  It has 12 subunits, again made of dimers, but instead of a sphere  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
Figure 1.2 Space fillings models of HSP16.5 and HSP16.9. 
A. Space filling model of the structure of HSP16.5, an oligomer of 24 subunits.  The 
front 1/3 is removed to show the hollow interior.  It is colour coded in tetramers, with 
each subunit in the tetramer represented by a different shade of the same colour.  Taken 
from (Kim, Kim et al. 1998) 
B. Space filling model of the structure of HSP16.9, an oligomer of 12 subunits.  It 
shows one of the two disks; again, different subunits of the same dimer are represented 
by a different shade of the same colour.   Taken from (van Montfort, Basha et al. 2001). 
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they form a double disk structure, with each disk encompassing six subunits.  The 
structure is shown in Figure 1.2B. 
The small size and spherical nature of the sHSPs indicate a marked similarity 
between these protein chaperones and nanoparticles.  Therefore, although they are not 
synthetic, the sHSPs could also be considered as nanoparticles. 
There is no crystal structure available for αB-crystallin because the polydisperse 
nature of its assembled state means there is no regular unit, however fragments have been 
crystallised.    Recently, solid-sate NMR has been used for αB-crystallin characterisation, 
and has given insight into the structure of the dimer, showing a new curved shape, (Jehle, 
Rajagopal et al. 2010) leading to predictions of the oligomeric structure.  However, this 
still only uses average subunit numbers due to polydispersity.   Data like this, along with 
rough structures predicted from homology with the two known sHSP structures is the 
closest to the actual structure that has yet been achieved. 
 
 
1.2.4.2. The chaperone mechanism - αB-crystallin 
 
The size of the αB-crystallin subunit is about 20 kDa.  It exists predominantly in the lens 
of the eye, where it forms a heteromer with its homolog, αA-crystallin.  Together they 
make the sHSP α-crystallin, a polydisperse oligomer, whose size ranges from about 200 
kDa to 800 kDa.  α-crystallin makes up about 50% of the lens proteins, and helps to 
maintain lens transparency by preventing aggregates from forming. While αA-crystallin is 
found only in trace amounts in non-lens tissues, αB-crystallin distribution is ubiquitous 
(Augusteyn 2004).  
 As mentioned above, the exact mechanism by which αB-crystallin carries out its 
chaperone function is still unknown.  The first step in determining the mechanism is 
discovering the binding sites for both substrates and oligomerisation.  Ghosh and Clark 
used protein pin array technology to identify the oligomerisation sites on the αB-crystallin 
monomer (the binding sites to αA-crystallin and αB-crystallin) (Ghosh and Clark 2005).  
The sites were present in all three of the domains, and were similar to sites known to be 
important for substrate binding: as is the nature of protein chaperones, proposed binding 
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sites are hydrophobic.  The N-terminal, especially, is thought to be important for both 
oligomerisation and substrate binding (Aquilina and Watt 2007), since the removal of the 
N-terminal of the yeast sHSP, HSP26, resulted in loss of both oligomerisation and 
chaperoning; although clearly one could be the result of the other (Haslbeck, Ignatiou et 
al. 2004). 
 Like the other protein chaperones, it is thought that sHSPs bind to a large range of 
substrates.  However, there are several sHSPs (in humans there are ten) and different 
sHSPs are found in the same cellular locations, suggesting that they have different 
specificities for different clients.  This idea is backed up by the fact that the N-terminal is 
the most variable region of the sHSPs, and it is this region that largely governs substrate 
binding (Haslbeck, Franzmann et al. 2005), although there is some variation in the C-
terminal tail which is also thought to contribute to client selection (Ghosh, Shenoy et al. 
2006).   
 It is not yet known whether substrate binding involves a conformational change, 
subunit exchange or dissociation of the oligomer; at least one of these mechanisms must 
be implicated if the same sites are used for oligomerisation and substrate binding. 
Additionally, the crystal structure of wheat HSP16.9 shows that the hydrophobic regions 
of the N-terminal are buried in the oligomer (van Montfort, Basha et al. 2001), and so 
clearly they must be liberated in order to bind to non-native proteins.  However, this does 
not necessarily hold true for all sHSPs.  
sHSPs are dynamic oligomers, and thus exchange subunits constantly, as can be 
demonstrated in several ways.  For example, mass spectrometry has been used to monitor 
oligomer size of α-crystallin, where it was found to change following the loss or gain of a 
subunit (Aquilina, Benesch et al. 2005).  Thus, it could be that the subunits bind substrate 
during this process, when they are dissociated and all of the binding sites are exposed 
(Lindner, Kapur et al. 1998).  This is supported by observations that under stressful 
conditions, which trigger higher chaperone activity in sHSPs, there is an increase in 
hydrophobicity.  Further evidence for this theory can be found in Surface Plasmon 
Resonance (SPR) data from Liu et al (Liu, Ghosh et al. 2006), which shows that increased 
subunit dynamics, caused by thermal stress, leads to increased chaperoning: a result 
already previously shown for αA-crystallin (Bova, Ding et al. 1997).   However, there is 
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data that contradicts this model: the subunits of HSP26 were crosslinked together to 
prevent subunit dissociation, but chaperoning was still observed (Franzmann, Wuhr et al. 
2005).  Similarly, Aquilina et al. showed that when αA-crystallin is mutated to decrease 
subunit dynamics, the rate of chaperoning is not affected (Aquilina, Benesch et al. 2005).  
These results suggest that it is not subunit dissociation but another mechanism, perhaps a 
change in conformation, which allows substrates to bind to the binding sites. Whether the 
chaperone mechanism is universal for all sHSPs is unknown.  
 sHSPs bound to their substrates do not exist freely, but are instead still in stable 
complexes.  The substrates are held in these complexes and so cannot aggregate.  One 
sHSP can bind up to one substrate per subunit, which is much more efficient than the 
other protein chaperones (Haslbeck, Franzmann et al. 2005).  In the lens it has been 
proposed that this is irreversible (Horwitz 2003), and once substrates are bound in these  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Proposed model of 
the mechanism of sHSP 
chaperoning.   
The sHSP oligomer either 
changes conformation or a 
subunit dissociates in order to 
bind to the non-native protein.  
The sHSPs bound to their 
substrates form a complex to 
prevent aggregation until an 
ATP-dependent protein 
chaperone refolds the protein 
and liberates the sHSP.  Taken 
from (Haslbeck, Franzmann et 
al. 2005) 
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complexes, they remain there.  This is because the lens is a closed, avascular system, 
lacking organelles and with a very specific protein profile.  The α-crystallin simply 
prevents the non-native proteins from compromising the optical properties of the eye, but 
it cannot refold them.  In other cells, however, this would not make sense, as they possess 
the ability to refold the proteins.  Therefore they are transferred instead to other protein 
chaperones, and with the help of ATP, refolded (Lee and Vierling 2000).  A general 
outline of the mechanism of sHSPs is shown in Figure 1.3. 
 
 
1.2.5. Nanoparticle chaperones 
 
The implementation of nanoparticles as synthetic chaperones is a subject that has received 
interest in the last decade.  As previously mentioned, the surface of nanoparticles can 
usually be easily modified, and can thus be adapted to have chaperoning properties.  The 
small size of nanoparticles means they also have a very high surface area to volume ratio, 
and thus any surface property which they possess will be displayed at a relatively high 
level.  Therefore if nanoparticles can be developed to have chaperone properties, they will 
potentially be very efficient chaperones.  However, it is not simply a case of the smaller 
the better, as if the nanoparticle is too small the curvature will be too big for the substrate 
to bind well to it, and so a compromise is reached at nanoparticles at the larger end of the 
scale (Fei and Perrett 2009).  
Biological chaperones bind to their substrates through hydrophobic interactions 
between their own hydrophobic regions and those of their clients.  This concept has been 
used in nanotechnology, using amphiphilic polymers modified with hydrophobic groups 
that self-assemble into micelle-like particles (Cavalieri, Chiessi et al. 2007).  Usually the 
polymers would form micelles with a hydrophobic core and hydrophilic surface, but the 
addition of the hydrophobic groups causes them to be displayed.  Consequently the 
surface of the nanoparticle is hydrophobic, allowing it to chaperone non-native proteins.  
Nanoparticles have also been made that interact with non-native proteins in a different 
way: by displaying charged functional groups on the surface, a nanoparticle can bind to 
the substrate using electrostatic interactions instead of hydrophobic ones.  One example of 
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this is a gold nanoparticle, functionalised with 2-(10-mercaptodecyl) malonic acid 
(AuDa), which is very negatively charged (De and Rotello 2008).  It was tested on three 
proteins, all of which were denatured thermally, and the nanoparticles not only prevented 
their aggregation, but assisted with their refolding.  They were dissociated using NaCl, 
and the substrates’ enzymatic activity was restored.   Raghava et al provided another 
example of this, using simple, unmodified titanium oxide (Ti02) nanoparticles (Raghava, 
Singh et al. 2009).  These provided similar results to the gold nanoparticles: they 
prevented aggregation, assisted refolding, and upon the addition of NaCl, dissociated, 
resulting in the original functional substrate.  
 The examples of nanoparticle chaperones discussed so far all have a similar mode 
of action to that of sHSPs.  Utilising a different approach, nanoparticles in the form of a 
nanogel have been developed to function more like the chaperonins (Akiyoshi, Sasaki et 
al. 1999) (Nomura, Ikeda et al. 2003).  Pullulan bearing a cholesterol group (CHP) self-
aggregates in water to form the nanogel, which traps non-native proteins (denatured 
thermally or chemically using GdmCl) within.  Once refolded, β-cyclodextrin triggers the 
release of the substrate, and so is acting in a similar manner to a co-chaperone or ATP.   
 Therefore, overall, nanoparticles can have the capability to act as good protein 
chaperones, an area which requires further investigation. 
 
 
1.3. This project 
 
 
1.3.1. The Burkhard nanoparticles as chaperones 
 
Section 1.2.5 demonstrates that nanoparticles can act as very effective protein chaperones, 
as do the non-synthetic sHSPs.  The purpose of this project, therefore, is to investigate 
whether the peptide nanoparticles developed by the Burkhard group also work as good 
protein chaperones.   
The nanoparticles that will be utilised are composed almost entirely of coiled-coils 
(Figure 1.1).  Coiled-coils are stabilised by a ‘knobs into holes’ interaction model, first 
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proposed by Crick (Crick 1953) in which apolar side chains pack into a hydrophobic core 
(Burkhard, Stetefeld et al. 2001).  The de novo trimeric coiled-coils designed by the 
Burkhard group are especially stabilised by hydrophobic interactions between coils, and 
contain a hydrophobic seam running along the length of them (Raman, Machaidze et al. 
2006) (Burkhard, Meier et al. 2000).  The pentameric coiled-coils from the COMP protein 
again use hydrophobic interactions, and it actually contains a long hydrophobic indent 
(Malashkevich, Kammerer et al. 1996). As protein chaperones use hydrophobic regions to 
bind to hydrophobic regions on their substrates, this means that, although designed with a 
different purpose in mind, these nanoparticles could function as efficient protein 
chaperones.   
Furthermore, these nanoparticles display a small peptide on their surface (Figure 
1.1D).  This peptide contains a large number of prolines, which will cause it to lack 
secondary structure.  Its amino acid sequence also renders it neutral and lacking 
hydrophobicity.  This peptide can thus be compared to the C-terminal tail of αB-crystallin, 
which shares similar features, and so this peptide could perhaps also provide chaperone 
activity.   
It is easy to see similarities between the spherical structure of the sHSPs, 
especially the crystallised structure of HSP16.5, and that of these nanoparticles.  
Consequently, a sHSP would serve as a good control for the nanoparticle. 
 
 
1.3.2. Nanoparticles enhanced with αB-crystallin sequences 
 
Additionally the nanoparticles will be enhanced with regions of αB-crystallin, which are 
solvent exposed and known to be substrate binding sites to find out if this improves their 
chaperone ability. 
 As described earlier (section 1.1.5. Antigen delivery and immunisation), these 
peptide nanoparticles can be modified.  The monomer peptides can be adapted to replace 
the existing displayed peptide with any other peptide sequence, which will then, in theory, 
be displayed on the surface of the nanoparticle 60 times once it has self-assembled.  
Therefore, if sequences of αB-crystallin that are thought to be important to its chaperoning 
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(i.e. the substrate binding sites), are the sequences used then these regions will be 
displayed on the surface of the nanoparticles (see Figure 1.4).  This would then potentially 
create very efficient ‘super-chaperones’.  Four regions of αB-crystallin were selected for 
this function, varying in size and sequence.  Two (np1 and np3) are shorter peptides, 
covering one cluster of substrate binding sites, while the other two (np2 and np4) are 
longer and cover two clusters.  
 
 
1.3.3. Project outline 
 
Following from the previous two sections, in this project, first the ‘empty’ nanoparticles 
(those that do not contain regions of αB-crystallin) will be made and assembled, and then 
tested for their chaperone function.  Subsequently, the DNA of the nanoparticles will be 
modified to encode regions of αB-crystallin.  Four different αB-crystallin-containing 
nanoparticles will also be made, assembled and tested for chaperone function. 
 Transmission Electron Microscopy (TEM) will be used be check the assembly of 
the nanoparticles. 
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Figure 1.4 The αB-crystallin sites which will be included in the nanoparticles 
The binding sites of several of the substrates of αB-crystallin are marked onto its amino acid 
sequence.  The regions of αB-crystallin that will be used for the creation of four ‘super 
chaperones’ are shown on the sequence with square brackets.  Np1 includes the regions 38-
64, np2 is 38-92, np3 is 73-92 and np4 is 64-153.  These regions were picked for the 
substrate binding sites which they contain.  Adapted from a figure by Andrew Landsbury. 
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2.1. Chemicals 
 
Unless stated otherwise, all chemicals and reagents were purchased from Sigma (UK) 
Fischer Scientific (UK)  
 
 
2.2. Bioengineering of nanoparticle peptides 
 
P6c-Mal-np plasmids encoding the nanoparticle peptide were a kind gift from Peter 
Burkhard.  Three of the four αB-crystallin sequences to be inserted into the nanoparticle 
(np1, np2, np4) were ordered from Sigma Genosys.  Np3 was created by annealing 
primers.  αB-crystallin WT pcDNA3.1 (-) from Ming-Der Perng was used as a template. 
1µl of each of the forward and reverse primers was combined with 48 µl annealing buffer 
(100mM potassium acetate 30mM HEPES, 2mM Magnesium acetate (AnalaR) adjusted to 
pH 7.4 with KOH).  This was put into a PCR block (Hybaid MBS 0.2G), 95ºC for 4 
minutes, then 70ºC for 10 minutes.  This was cooled slowly to 4ºC.  This primer was then 
phosphorylated: 2µl was added to 1µl of T4 PNK buffer and 5µl MQ water and 1µl 10mM 
fresh ATP (5mg/ml MQ water and disodium salt to a final concentration of 1mM).  This 
was amplified; 37ºC for 30 minutes, 70ºC for 10 minutes and then 37ºC for a further 5 
minutes.  This was then allowed to cool to 4ºC. 
 This annealed oligonucleotide then had to be ligated into the p6c-Mal-np vector:  
2µl was added to 1µl 10x ligase buffers, 1µl of p6c-Mal-np vector cut with EcoR1 and 
SmaI restriction enzymes, 5µl MQ water and 1µl T4 DNA ligase.  This kept at room 
temperature for 3 hours and then at 4ºC overnight. 
 The other 3 primers were amplified by PCR; 94ºC for 2.5 minutes, followed by 25 
repeats of 94ºC for 30 seconds, a gradient of 56-68ºC for 30 seconds and 72ºC for 2 
minutes, and finally flowed by 72ºC for 3 minutes.  This was cooled to 4ºC.  These were 
all cloned into the pGEM
®
-T-Easy vector (Promega) and then the p6c-Mal-np vector 
following the previous method.  
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2.3. Transformation of nanoparticle peptide plasmids 
 
All 5 different p6c-Mal-np vectors and 50μl BL21 competent cells were thawed on ice.  
1μl of the DNA was added to the cells and mixed very gently.  The tube was incubated on 
ice for a further 30 minutes, and then heat shocked in a 42°C water bath for 45 seconds.  It 
was then returned to the ice for 10 minutes, 250μl of sterile Luria Bertain (LB) (1% 
tryptone (Lab M), 0.5% bacto yeast extract (Becton, Dickinson and Company), 1% NaCl) 
was added and the mixture was incubated at 37°C for 1 hour in a bacterial shaker, 225 
rpm.  Meanwhile agar plates were prepared.  Sterile agar (LB+ 1.5% agar (Melford)) was 
melted using a microwave, allowed to cool to 50°C, before 200mg/ml carbenicillin 
(Melford) and 30 mg/ml chloramphenicol were added.  25ml was poured onto each plate, 
and they were allowed to set.  20μl, 50μl and 200μl of the cells, now containing the 
plasmid, were spread onto 3 different plates, and they were left, upside-down, to incubate 
overnight at 37°C.  They were then moved to 4°C to prevent further growth. 
 
 
2.4. Expression of nanoparticle peptides 
 
A pipette tip was used to pick a bacterial colony from the transformed plates, and was 
inoculated into 20ml of sterile LB, with 200mg/ml carbenicillin, 30 mg/ml 
chloramphenicol and 0.05% glucose (Merck), and grown overnight at 37°C at 225 rpm.  
1L of sterile LB with the same additions was inoculated 1:100 with the overnight culture, 
and was grown at 37°C at 170rmp until O.D600 had reached 0.5-0.6 (about 3 hours), 
measured with a DU640 spectrometer (Beckman).  0.5ml of the overnight culture was put 
in an Eppendorf tube with 0.5ml 80% glycerol to make a glycerol stock, which was stored 
at -80°C.  Isopropyl-1-thio-β-D-galactopyranoside (ITPG) (Melford) was added to a final 
concentration of 1mM to induce expression of the nanoparticle peptides, and the culture 
was incubated for a further 3 hours.  The culture was then harvested by centrifugation at 
8,000rpm for 30 minutes at 4°C using a JlA-8.1000 rotor (Beckman) in a floor centrifuge 
(Beckman Coulter).  The supernatant was discarded and the pellet was resuspended in 
20ml lysis buffer (9M Urea, 100mM NaH2PO4 (BDH), 10mM Tris (Melford)) pH 8.0; this 
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was stored at -20°C until used.  1ml samples were removed from the culture before 
induction and before harvesting.  These were centrifuged for 5 minutes at 13,200rpm 
using a benchtop centrifuge (IEC Micromax), the pellets were resuspended in 200μl 1x 
sample buffer (as described in (Laemmli 1970) and were boiled for 5 minutes at 95°C.  10 
μl was run using 14% (w/v) sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) to confirm that induction was successful.  
 
 
2.5. Purification of nanoparticle peptides 
 
Due to the fact that the nanoparticle peptides were designed to include a His-tag, their 
purification was relatively simple.  The resuspended pellet was thawed, and returned to 
room temperature.  The cells were solubilised by sonication, using a Soniprep 150 
sonicator (MSE) at amplitude of 30 mincrons for 1 minute and centrifuged at 20,000g for 
40mins at 22°C using a JA-20 rotor (Beckman).  1ml of His-Select Nickel Affinity Gel 
was washed twice with 5ml water and twice with 5ml lysis buffer, then added to the 
supernatant, and incubated overnight at 20°C with gentle shaking  This allowed time for 
the nanoparticle peptides to bind to the His-tag beads. The mixture was transferred to a 
free standing 10ml column, and washed with 20ml lysis buffer, pH 7.5, by slow addition 
of 1ml steps.  Fractions of 1.5ml were collected in Eppendorf tubes.  The beads were then 
washed in the same way with 20ml washing buffer 1 (100mM PO4, 9M Urea; pH 6.8), 
20ml washing buffer 2 (20mM citrate, 9M Urea; pH 5.9) and 20ml washing buffer 3 
(20mM citrate, 9M Urea; pH 4.5).  The nanoparticle peptides were then eluted from the 
beads using 20ml elution buffer (lysis buffer with 1M imidazole; pH 8.0) and collected in 
1ml fractions.  The fractions were run using SDS-PAGE; fractions containing nanoparticle 
peptides were pooled and dialysed overnight, with gentle stirring, into refolding buffer 
(20mM Tris pH 7.5, 150mM NaCl, 8M Urea, cleaned by adding Amberlite (Merck) and 
vacuum filtration using 0.2μm cellulose nitrate membrane filters (Whatman)).  The 
concentration of the nanoparticle peptides were then quantified using Pierce BCA 
(bicinchoninic acid) protein assay kit (Thermo Scientific), adjusted to 0.3mg/ml and 
stored in 0.5ml aliquots in Eppendorf tubes at -80°C.  The beads were cleaned by washing 
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with 2 volumes of deionised water, 5 column volumes of 2% SDS (Biorad), and then 30% 
ethanol, as per the product information, and stored in 30% ethanol at 4°C for reuse.  
 
 
2.6. Assembly of nanoparticles 
 
Nanoparticles were assembled in accordance to (Schroeder, Graff et al. 2009) (Pimentel, 
Yan et al. 2009) with some slight modifications.  They were thawed, diluted to 0.1 mg/ml 
and dialysed overnight with stirring in assembly buffer (20mM Tris pH 7.5, 150mM NaCl, 
8M urea).  They then underwent stepwise dialysis with decreasing concentrations: 6M, 
4M, 2M, 1M until 0M, each either for 3h or overnight, with stirring.  This was carried out 
at room temperature.   
 
 
2.7. Expression of αB-crystallin  
 
A Glycerol stock of BL21 cells containing αB-crystallin was a kind gift from Andrew 
Landsbury.  As with the nanoparticle peptides (see section 2.4. Expression of nanoparticle 
peptides), 20ml of LB was inoculated with 2μl of the glycerol stock, along with 50mg/ml 
carbenicillin, 34 mg/ml chloramphenicol and 0.05% glucose, and the culture was grown 
overnight at 37°C at 225rpm.  Again, 10ml of the inoculum was then added to 1L of LB 
and the bacteria was grown at 37°C, 170rpm, until it reached an O.D600 of 0.5-0.6, this 
time however, it was then induced with ITPG to a final concentration of 0.5mM.  It was 
grown for a further 3 hours, and then harvested in a similar way to before, although 
instead of using lysis buffer in which to resuspend the bacterial pellet, 20ml resuspension 
buffer was used (50mM Tris pH 8.0, 1mM EDTA, 100mM NaCl, 10mM MgCl2 (BDH), 
with 1 x protease inhibitor tablet (Roche) and 0.2mM phenylmethanesulfonyl fluoride 
(PMSF) (Calbiochem), dissolved in 100% ethanol added just prior to use).  Again, SDS-
PAGE was used to ensure induction had occurred, and the resuspended bacterial pellet 
was stored at -20°C. 
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2.8. Purification of αB-crystallin 
 
αB-crystallin is soluble in the bacterial pellet, and so a soluble protein extraction was used 
to begin the purification procedure.  Firstly, three freeze-thaw cycles were carried out to 
break open the bacterial cells. Each time, the bacteria was frozen and then returned to 
room temperature.  Storage of the bacteria at -20°C was the first freeze step.  After this, 
and once it was back at room temperature, lysozyme was added to a final concentration of 
0.25-1mg/ml to further break open the resuspended bacteria.  It was mixed well with a 
dounce plunger.  It was then shaken for 15 minutes, using a bacterial shaker, at 37°C, 
70rpm.  Next, the mixture was dounce homogenized on ice to complete the lysis of the 
bacteria.  It was centrifuged for 15 minutes, using a JA-20 rotor, at 16,000rmp, and at 
room temperature.  The cell debris and insoluble proteins were pelleted and discarded, 
while the supernatant was retrieved.  Benzonase nuclease was added to a final 
concentration of 10units/ml, and the solution was well mixed, again with a dounce 
plunger.  It was then incubated at room temperature, with gentle mixing, for 30 minutes, 
before 5% P.E.I was added to a 1000 x final dilution and the solution was incubated for a 
further 10 minutes, again with gentle mixing, this time on ice.  It was again centrifuged 
using a JA-20 rotor, although the speed was 20,000rpm, the temperature 4°C and the 
length of time 20 minutes.  This pelleted the DNA and RNA, which was discarded, and 
the supernatant, containing soluble proteins was kept.  This concluded the extraction of 
αB-crystallin from the bacterial cells, but it then had to be purified using high performance 
liquid chromatography (HPLC), for which a smaller volume than 20ml was required.  
Therefore, the solution was then concentrated using an Amicon ultra centrifugal filter, 
MW 10,000kDa (Millipore) at 4,500 rpm, 4°C for 15 minutes (Jouan CR4-22 centrifuge), 
repeated until the volume was 5ml.    
 The first HPLC step used for αB-crystallin purification was running an anion 
exchange (TMAE) column (Hitachi Merck, L-4250 UV-Vis detector, L-6210 intelligent 
pump).  Line A was put into buffer A (20mM Tris pH 7.4, 1mM MgCl2, 1mM EDTA, 
1mM Dithiothreitol (DTT) (Melford), 0.2mM PMSF, 0.2μm vacuum filtered) and the 
column was equilibrated overnight, with a pump speed of 2ml/min.  The protein solution 
was dialysed overnight at 4°C with stirring, also into buffer A.  Equilibration was 
 31 
confirmed by comparing pH and UV reading of the column flow through with that of 
buffer A.  Line B was then put into buffer B (buffer A + 1M NaCl, also 0.2 μm vacuum 
filtered), the protein solution was injected onto the column, and chromeleon software was 
used set the gradient.  As αB-crystallin should not bind to the column, it should be eluted 
in the first 15 minutes.  Therefore the column was set to stay at 100% buffer A for 20 
minutes, increase to 100% buffer B between 20 and 40minutes and stay at 100% buffer B 
until 70 minutes.  It ran at 1ml/min, and so 1ml fractions were collected (Biorad 2110 
fraction collector) in Eppendorf tubes.  SDS-PAGE was used to identify the fractions that 
contained αB-crystallin and these were pooled. 
 Next, the solution was further purified by size exclusion chromatography (SEC).  
The column was equilibrated overnight using SEC buffer A (20mM Tris pH 7.4, 100mM 
NaCl, 0.2 μm vacuum filtered), again using 2ml/min through column A.  The solution was 
concentrated to 0.25ml, and once equilibration was confirmed, it was injected onto the 
column.  1ml fractions again were collected and SDS-PAGE was used to identify αB-
crystallin.  Those containing αB-crystallin, but not impurities, were pooled, and BCA was 
used to determine the concentration, it was adjusted using the SEC buffer, and aliquots at 
a range of volumes and concentrations were stored at -80°C.   
Each time a column was used it was cleaned afterwards.  First 0.5M NaOH was 
run through for 1 hour, at a speed of 2ml/min to wash out the buffers and to sanitise.  Next 
MQ water (Millipore) was run through at 2ml/min, until the flow through had returned to 
pH 7.0 (determined using pH indicator strips (BDH)).  Finally, column storage buffer (1M 
NaCl, 0.02% (v/v) sodium azide) was run through at 2ml/min for 1 hour.  All buffers were 
0.2 μm vacuum filtered.  The machine was switched off, and all 3 lines were left in MQ 
water.    
 
 
2.9. Expression of desmin 
 
The glycerol stock of BL21 cells with the desmin plasmid was another gift from Andrew 
Landsbury.  The expression of desmin was carried out in exactly the same way as αB-
crystallin (see section 2.7. Expression of αB-crystallin). 
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2.10. Purification of desmin 
 
As desmin is an insoluble protein, the first step of purification was an insoluble protein 
extraction.  This begins in the same way as the soluble protein extraction (see section 2.8: 
Purification of αB-crystallin), since the same method is used to break open the bacterial 
cells.  The resuspended pellet underwent three freeze-thaw cycles, and upon reaching 
room temperature, lysozyme was added to a final concentration of 0.25-1mg/ml.  It was 
mixed well with a dounce plunger, shaken at 37°C for 15 minutes, homogenised and then 
centrifuged for 15 minutes, room temperature, 16,000rpm using a JA-20 rotor.  This time, 
however, the pellet was saved and the supernatant was discarded.  It was resuspended in 
20ml buffer 1 (20mM Tris pH 7.4, 150mM NaCl, 5mM EDTA, 1mM EGTA, with 0.5mM 
DTT, 0.2mM PMSF and 1% v/v triton added prior to use), and this was homogenised.  
Benzonase nuclease was added to a final concentration of 10units/ml, was mixed well, and 
incubated for 30 minutes at room temperature with gentle mixing.  It was then centrifuged 
again at 20,000rpm for 15 minutes, this time at 4°C.  The supernatant was discarded and 
the pellet was resuspended in 20ml buffer 2 (20mM Tris pH 7.4, 150mM NaCl, 5mM 
EDTA, 1mM EGTA, with 0.5mM DTT, 0.2mM PMSF, 0.5% v/v triton and 1.5M KCl 
added prior to use), homogenised and mixed gently at room temperature for 15 minutes.  
After another centrifugation with the same conditions, the pellet was resuspended and 
homogenised in buffer 3 (20mM Tris pH 7.4, 150mM NaCl, 5mM EDTA, 1mM EGTA, 
with 0.5mM DTT and 0.2mM PMSF added prior to use), and again mixed gently for 15 
minutes at room temperature.  It was again centrifuged, and this time resuspended and 
homogenised in 5ml desmin TMAE buffer A (7M Urea, 10mM Tris pH 8.0, 1mM EDTA, 
1mM DTT, 0.2mM PMSF, cleaned with amberlite and vacuum filtered.  It was mixed 
gently at room temperature until the pellet had dissolved, and centrifuged at 30,000rpm 
for 30 minutes at 4°C using an MLA-80 rotor.  It was then purified using a TMAE 
column, in the same way as described for αB-crystallin (see section 2.8. Purification of 
αB-crystallin), but using a linear gradient where % buffer B (buffer A + 1M NaCl) 
increases by 1%/min.  The fractions containing desmin were again identified using SDS-
PAGE, pooled the concentration was quantified using a BCA protein assay.  The 
concentration was adjusted to 1mg/ml using TMAE buffer A and frozen in 1ml aliquots.    
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2.11. Citrate synthase chaperone assay 
 
Citrate synthase purified from porcine heart was bought from Sigma.  Before it can be 
used in a chaperone assay, it must be dialysed overnight at 4°C into CS buffer (50mM Tris 
pH 8.0, 2mM EDTA).  Subsequently, it can be stored at 4°C.  The protein concentrations 
of the citrate synthase and the chaperone (either assembled nanoparticles or αB-crystallin) 
were then quantified using a BCA assay.  The concentration of citrate synthase was 
adjusted to 0.5mg/ml using CS buffer.  The 6 micro cuvettes that are used for the assay 
were meanwhile cleaned by 30 minutes sonication (Branson 1510 sonicator) in 5% 
Teknon 100 detergent, rinsed and allowed to air-dry.  For each of the chaperones, citrate 
synthase (the substrate) was used at a final concentration of 0.15mg/ml, and the chaperone 
was used at both a 2:1 and 20:1 substrate:chaperone ratios.  The assay was carried out 
using the kinetics/time function on the DU640 spectrometer. For each cuvette, the sample 
was compiled: lane 1 was a negative control (only chaperone), lanes 2-4 were the 
chaperone assays (chaperone and substrate, three identical repeats), lane 5 was a positive 
control (only substrate) and lane 6 was a blank.  The negative control contained an 
equivalent amount of chaperone buffer (either αB-crystallin SEC buffer or nanoparticle 
0M Urea refolding buffer) to remove the possibility that any chaperone effect seen is due 
to the buffer present.  Each sample was made up 220μl using CS buffer.  The machine was 
set to 44°C and allowed to reach full temperature before the assay was begun.  The 
cuvettes were not pre-warmed.  All 6 cuvettes were then loaded with the sample, tapped 
and wiped to remove air bubbles and smears, and inserted into the machine.  It was run for 
30 minutes, taking readings every 15 seconds at OD360.  The cuvettes were rinsed and 
allowed to air-dry between each assay.  Each of the four conditions was repeated three 
times, each time with separately prepared citrate synthase and separately assembled 
nanoparticles. 
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2.12. γ-crystallin chaperone assay 
 
γ-crystallin, purified from bovine lens’ was a kind gift from Frederique Tholozan, in a 
buffer of: 2mM EGTA, 1Mm MgCl2, 1mM DTT.  This assay was only used for 
nanoparticles, and not for αB-crystallin, due to the high temperature needed.  The method 
was as for the citrate synthase chaperone assay (section 2.11, citrate synthase chaperone 
assay), apart from the following two differences: the samples were made up to 220μl using 
0M Urea folding buffer and the assay was run at 70°C.  
 
 
2.13. Desmin assembly and sedimentation assay 
 
The concentrations of desmin, αB-crystallin and assembled nanoparticles were requantifed 
using a BCA assay.  300μl samples were compiled using 0.5mg/ml desmin at a ratio of 1:1 
with chaperone, made up to volume using desmin TMAE buffer A.  Controls of each of 
the three proteins by themselves were also made, and each of the five samples was 
repeated three times.  They were all dialysed overnight in desmin assembly buffer (20mM 
Tris pH 8.0, 1mM DTT, 1mM EDTA, 4M Urea, cleaned with amberlite and vacuum 
filtered) at room temperature.  They then underwent stepwise dialysis with decreasing 
concentrations of Urea (2M, 0M) each for 3 hours at room temperature.  The samples were 
then transferred into the final assembly buffer (20mM tris pH 7.0, 50mM NaCl) for 
overnight dialysis, one of each of the five samples were put at 22°C (room temperature), 
37°C (37°C room) and 44°C (oven). 
 The next day, the results were processed using a sedimentation assay.  They were 
removed from their dialysis bags, and 50μl of each of the 15 samples were centrifuged in 
Eppendorf tubes at for 10 minutes at low speed (2,450g) at room temperature using a 
benchtop centrifuge (Eppendorf 5417R).  50μl was also centrifuged on a 0.85M sucrose 
cushion for 30 minutes at high speed (30,000rpm), using a TLS-55 swing rotor (Beckman) 
in a Beckman Coulter optima max ultracentrifuge, at room temperature.  For both 
centrifugations, the supernatant was removed carefully from the pellet, and the pellet was 
redissolved in 150μl 1x sample buffer.  All of the protein present in the supernatant was 
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precipitated using methanol-chloroform precipitation (see section 2.14. Methanol-
chloroform precipitation), and also redissolved in 150μl 1x sample buffer.  All 60 samples 
were boiled for 5 minutes at 95°C, and 10μl of each was run on a 14% gel using SDS-
PAGE.  Once they had been run, the gels were fixed for 20 minutes using fixer solution 
(50% methanol, 10% acetic acid), stained for 25 minutes using comassie blue (50% v/v 
methanol, 10% v/v acetic acid, 0.25% w/v Coomassie brilliant blue R-250(Biochemical)) 
and then destained using destain solution (10% methanol, 5% acetic acid) until the bands 
were clear enough for quantification.  The gels were photographed using Fujifilm 
intelligent darkroom technology and image gauge software was used to quantify the band 
intensity, and hence the amount of protein, on the gels.  This experiment was repeated four 
times, each time with newly assembled nanoparticles and with a new set of desmin 
buffers.        
 
 
2.14. Methanol-chloroform precipitation  
 
Methanol-chloroform precipitation was used to precipitate any protein present in the 
supernatant after the sedimentation assays.  To the sample, 4x sample volume of 
methanol, 1x sample volume of chloroform and 3x sample volume of water were added.  
This was vortexed, and then centrifuged at 12,000rpm for 5 minutes in a benchtop 
centrifuge.  The top layer was discarded, and 3x sample volume of methanol was added.  
The sample was again vortexed and centrifuged in exactly the same way.  The supernatant 
was discarded, leaving the precipitated protein. 
 
 
2.15. Preparation for TEM 
 
To prepare grids for use in the transmission electron microscope, mica coated in carbon 
was dipped into an Eppendorf lid containing 345μl buffer and 5μ sample.  It was then put 
into 1% uranyl acetate (AnalaR).  The carbon was lifted from underneath onto a 3.05mm 
copper grid (Agar), and then used in the TEM. 
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3.1. Bioengineering, expression and purification of the nanoparticle peptides 
 
The plasmid p6c-Mal-np encoding the engineered nanoparticle (Schroeder, Graff et al. 
2009) (Pimentel, Yan et al. 2009) was transformed directly into BL21 cells.  It was also 
spliced and ligated to include a region of αB-crystallin DNA before transformation.  Four 
different nanoparticles were created that were designed to contain regions from αB-
crystallin important in binding client proteins.  These expression vectors were p6c-Mal-
np1 (containing region 38-64 of the amino acid sequence), p6c-Mal-np2 (38-92), p6c-Mal-
np3 (73-92) and p6c-Mal-np4 (64-152) (Figure 1.4).  The transformed cells were cultured 
and induced to express the nanoparticle peptides (Figure 3.1A, tracks 1 and 2).  These pre- 
and post-induction samples show clearly that that the addition of ITPG led to the 
production of a protein with a molecular weight of about 14 kDa (arrow).  Given that the 
nanoparticle peptides should have a calculated molecular weight of 12.5 kDa, it can be 
assumed that the induced protein was in fact the nanoparticle peptide.  A large quantity of 
the protein was produced in comparison to the host proteins, so this is clearly a very 
efficient expression vector.   
   The nanoparticles were purified by affinity chromatography using the 
bioengineered his-tag and a nickel affinity column. The elution fractions (Figure 3.1A, 
tracks 6-10) of the nanoparticle peptides show two bands, one at 14 kDa (arrow), which is 
assumed to be the monomer, and another at 43 kDa (double arrow).  This is a major band; 
however it cannot be seen in any of the other lanes.  Therefore it can be concluded that 
this band is from a protein which was not present in that form during the culturing and 
harvesting of the bacteria.  The molecular weight of this band is about three times that of 
the monomer, thus it is likely that the band represents a trimeric form of nanoparticle 
peptide, which was previously prevented from oligomerisation by bacterial factors.  
Although proteins usually retain little secondary structure in SDS, the monomers contain 
trimeric coiled-coil oligomerisation domains, and it has previously been seen that trimeric 
coiled-coils can be SDS-resistant (Chen, Lu et al. 2010) (Hayashi, Yamasaki et al. 1995).  
More structural investigations would be needed to confirm this.  
The gels of the purification of the other nanoparticles (Figure 3.1B) do not differ 
from the ‘empty’ nanoparticles; the αB-crystallin did not appear to affect the process. 
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Figure 3.1 Nanoparticle peptide expression and purification gel (SDS-PAGE)  
A E.coli BL21 were transformed with the plasmid p6c-Mal-np and protein expression 
induced by the addition of IPTG. Comparing a sample of the pre-induction culture (track 1) 
with a sample from an IPTG induced culture (track 2) shows the expression of one 
additional band (arrow) corresponding to the nanoparticle. Once sonicated and centrifuged, 
the nanoparticle was present both in the supernatant (track 3) and the pellet (track 4) 
indicating that not all of the cells had been lysed.  The supernatant was incubated with his-
beads and put onto the column; the lack of nanoparticle in the flow-through (track 5) shows 
binding to the beads was efficient.  After washing, the nanoparticles were eluted (tracks 6-
10) and fractions containing nanoparticles (fractions 1-7) were pooled (track 11); these were 
very clean.  The protein ladder is on the right, with associated weights labelled in kDa.  
B Reduced gels of the other four nanoparticles showing ladder (track 1), pre-induction 
(track 2), post-induction (track 3) and purified nanoparticle (track 4).  All show the same 
features as in A. 
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3.2. Assembly of the nanoparticles 
 
 
3.2.1. Assembly of ‘empty nanoparticle’ 
 
Once purified, the nanoparticle peptides were assembled. From computer modelling, they 
should self assemble to form 60-mers, with a diameter of 16nm. However, it was 
previously found that in practice the amount of monomers varied, and was affected by 
buffer conditions and concentration.  At the conditions used here the average number of 
monomers was 44, determined by analytical ultracentrifugation, and the diameter was 
16nm, determined by electron microscopy (Raman, Machaidze et al. 2006).   
The design of the nanoparticles lent itself particularly well to their assembly; after 
stepwise dialysis into a 0M urea buffer they should self-assemble.  Following successful 
assembly, highly symmetrical spherical nanoparticles should form; this was verified with 
TEM.  Figure 3.2A shows that nanoparticles did indeed form.  Most of the nanoparticles 
were in the shape of a regular sphere, although there was some variation, and the size 
varied between 15-22 nm.     
 One interesting finding was that when run on a SDS-PAGE gel, these assembled 
nanoparticles did not produce a band.  Upon closer inspection, there was found to be 
staining between the stacking gel and the resolving gel, indicating a protein that was too 
big to enter the resolving gel.  As the molecular weight of the monomer was 12.5 kDa, the 
molecular weight of a 60-mer would therefore be 750 kDa, certainly too large to run onto 
the gel.  It is likely that, again, the trimeric coiled-coils were resisting SDS solubilisation; 
the design of the nanoparticle would mean that if this is the case the structure would 
remain as a whole. 
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Figure 3.2 TEM image of assembled nanoparticles 
A. Assembled ‘empty’ nanoparticles - np 
B. Aggregated nanoparticle peptides containing αB-crystallin region – np1.  This is 
representative of all four different αB-crystallin containing nanoparticles. 
Both taken at 60000x magnification and stained with 1% uranyl acetate 
 
A 
B 
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3.2.2. Assembly of nanoparticles displaying regions of αB-crystallin 
 
The nanoparticles containing αB-crystallin regions were assembled in the same way as 
those without.  Again they were expected to form spheres, with the αB-crystallin regions 
displayed on their surfaces.  It was unknown whether the addition of the regions would 
effect the number of monomers in a nanoparticle; the addition of a region of the SARS 
virus to the monomer led to particles of 110 monomers being formed (Pimentel, Yan et al. 
2009)  
However, upon dialysis out of urea all four of the samples produced a visible white 
precipitate that was not seen for np.  This suggested that the nanoparticle peptides had 
aggregated instead of forming spheres.  This was verified for one of the samples, np2 by 
TEM (Figure 3.2B). 
 
  
3.3. Chaperone assays 
 
As the nanoparticles containing αB-crystallin regions did not form, only the ‘empty’ 
nanoparticle, np, was used in the chaperone assays.  To test for chaperone function; that is, 
the ability to stop non-native proteins from aggregating, three assays were used.  In the 
first two, the client protein was put under denaturing conditions, in which it would 
ordinarily aggregate, both with and without nanoparticles present.  Chaperone function 
would be indicated by the nanoparticles preventing aggregation of the client proteins.  The 
two assays were carried out at very different temperatures to investigate the temperature 
range of activity.  The third assay, on desmin filaments, was different, instead of 
denaturing the substrate, the assay tested effect of the chaperone on filament-filament 
interactions; by preventing them it would prevent aggregation.    
Being the archetypal sHSP (small heat shock protein), and thus the natural small 
chaperone about which most is known, αB-crystallin was used as a control.   
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3.3.1. Citrate synthase chaperone assay 
 
In the citrate synthase chaperone assay, a temperature of 44°C was used to cause 
denaturation of the citrate synthase.  As the protein unfolds and aggregates, it causes the 
beam of light that passes through the cuvette to scatter, producing a higher OD.  
Therefore, with successful chaperoning, a lower OD is observed.  The results of this assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
chaperone, 
CS:chaperone %aggregation 
np, 1:20 20.6 ± 9.0 
np, 1:2 4.9 ± 1.9 
ab, 1:20 94.8 ± 5.8 
ab, 1:2 91.9 ± 6.8 
 
A 
Figure 3.3 Results of the citrate synthase 
chaperone assays 
A) Graph of % citrate synthase aggregation 
over time, as indicated by optical density 
(OD).  CS stands for citrate cynthase, ab for 
αB-crystallin and np for nanoparticle.  Data 
points show the mean result of nine repeats, 
and error bars represent one S.D. in each 
direction. 
B) Table of final % aggregation after 30 
minutes, relative to citrate synthase control. 
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are shown graphically in Figure 3.3, where the level of aggregation in the presence of each 
chaperone is compared to a positive control where the aggregation of citrate synthase is 
measured in the absence of a chaperone protein (Figure 3.3A).  The percentage 
aggregation after the full 30 minutes relative to control is also shown (Figure 3.3B).  Both 
of the chaperones were tested at a substrate-to-chaperone ratio of 2:1 and 20:1, and each 
assay was carried out in three sets of three (nine repeats).  The graph shows how 
remarkable the chaperone function of the nanoparticles was in this assay: at a ratio of 2:1 
there was virtually no aggregation, indicating complete chaperoning.  The result for the 
assay using αB-crystallin at the same concentration, however, was much more modest, 
with a final level of aggregation of 91.9%.  A lower value would be more expected, but 
nothing close to 4.9% (Hayes, Devlin et al. 2008) (Ghosh, Estrada et al. 2005).  The low 
level of αB-crystallin chaperoning could be due to error with protein concentration 
quantification, however the concentrations of both αB-crystallin and the nanoparticles 
were quantified in the same assay, and thus both would be subject to the same error.  This 
makes the results for the nanoparticles particularly impressive.   
 Whilst the result for the 2:1 assay were remarkable, the results for the 20:1 assay 
were, in some respects, even more so.  In this instance, there was a very small amount of 
chaperone relative to substrate, yet an impressive degree of chaperoning was still 
observed, with the final aggregation level only 20%.  Again chaperoning at this low level 
would not be expected for sHSPs; the result for αB-crystallin at the same ratio of 
aggregation of 94.8% ± 5.8, indicating virtually no chaperoning at all, is unsurprising.  
This high level of chaperoning for what is a relatively small concentration of protein 
suggests that the nanoparticles chaperone not only well, but also by a very efficient means.   
 
 
3.3.2. γ-crystallin chaperone assay 
 
The unfolding of γ-crystallin in this chaperone assay was again temperature induced, 
however in this instance a much higher temperature of 70°C, was used to denature the 
substrate.  At this temperature αB-crystallin formed flocculate aggreagates, so no sHSP 
was used as a control.  The results (Figure 3.4) are very similar to those for the citrate 
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synthase assay.  Again, the nanoparticles showed a very high level of chaperone function, 
with a final aggregation of 9.1% for a substrate-to-chaperone ratio of 2:1 and 23.9% for 
20:1.  This is further evidence that these nanoparticles function both well and efficiently as 
protein chaperones.   
 
 
 
 
 
γ-crystallin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
γ-crystallin : np % aggregation 
 1:20 23.9 ± 4.4 
 1:2 9.1 ± 4.0 
 
A 
Figure 3.4 Results of the γ-crystallin chaperone 
assays 
A) Graph of % γ-crystallin aggregation over time, as 
indicated by optical density (OD).  γc stands for γ-
crystallin and np for nanoparticle.  Data points show 
the mean result of nine repeats, and error bars 
represent one S.D. in each direction. 
B) Table of final % aggregation after 30 minutes, 
relative to γ-crystallin control. 
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The results also show the stability of the nanoparticles.  At 70°C, a temperature at 
which most proteins would become denatured, they have not lost any functionality.  This 
again illustrates how strong the interactions that hold the nanoparticles together are. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supernatant 
Supernatant 
Pellet Pellet 
Centrifuged at 
low-speed – only 
aggregated 
desmin is drawn 
into pellet
Centrifuged at high-
speed – all desmin is 
drawn into pellet, 
along with all 
chaperone bound to 
desmin
Aggregated desmin
Chaperone particle
Free desmin
 
Figure 3.5 Diagram to summarise low and high speed sedimentation assays 
When centrifuged at a low speed, only aggregated desmin will be found in the pellet, and 
so the more desmin in the supernatant, the less has aggregated and the better the 
chaperone.  Under high speed centrifugation all desmin will be drawn into the pellet, 
regardless of its aggregation state, and any chaperone bound to desmin will be pulled into 
the pellet too.  Therefore, the more chaperone found in the pellet, the higher the level of 
chaperone binding. 
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3.3.3. Desmin assembly chaperone assay 
 
This chaperone assay differs from the previous two; the client is not unfolded, instead 
filament-filament interactions are promoted.  Desmin is prepared for assembly by a  
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Low speed High speed 
Figure 3.6. Gels from the desmin assembly sedimentation assay.  
Samples were spun at both a low speed and a high speed.  The supernatants were 
precipitated using methanol-chloroform, and then resuspended in 1 x sample buffer.  
The Pellets were also resuspended in the same volume of 1 x sample buffer.  Samples 
were run on 14% SDS-PAGE gels.  P indicates pellet and S indicates supernatant.  The 
experiment was repeated four times: one example for each protein in each sample is 
shown for low and high speed, and at each of the three temperatures.  The density of the 
bands was measured using image gauge software, from which a bar chart was created to 
show the percentage of protein in the pellet for each sample. 
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sequential dialysis strategy.  It is then assembled into filaments at three different 
temperatures - 22°C, 37°C and 44°C - as the higher the temperature, the higher the level 
of filament-filament interactions; the assay measures the chaperone’s ability to prevent 
these interactions.  The process is carried out with desmin alone and in the presence of 
each chaperone.   They also both underwent the assay without desmin as controls.  The 
level of aggregation is determined by a sedimentation assay (summarised in Figure 3.5).   
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Figure 3.7 Graph of low speed and high speed sedimentation assays for desmin assembly 
chaperone assay 
Bars correspond to the % of the protein found in the pellet out of the total amount of the protein 
in the sample. Red bars represent the low speed centrifugation (chaperone assay), and blue bars 
the high speed (binding assay).  22, 37 and 44 refer to the temperature at which assembly took 
place, in °C.  Des stands for desmin, ab for αB-crystallin and np for nanoparticles.  Data points 
are the average of four repeats.  Anomalies were removed.  Error bars are one S.D from the 
average in each direction. 
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Post-assembly, the samples are centrifuged at a low speed.  Any aggregated 
filaments will be drawn down into the pellet, whereas unaggregated filaments will remain 
in the supernatant.  Therefore, the more chaperoning that occurs, the higher the proportion 
of desmin left in the supernatant.  The pellet and supernatant are then both run using SDS-
PAGE (Figure 3.6) and the density of the bands is determined using image gauge 
software, enabling comparison of the amount of protein in the pellet against the amount in 
the supernatant (Figure 3.7).  As previously discovered (see section 3.2. Assembly of the 
nanoparticles), the nanoparticles do not run well on the gel.  However, it was found that a 
better result was obtained if they were first precipitated and then resuspended in sample 
buffer.  This could be because the organic solvent is hydrophobic.  Coiled-coils are 
thermodynamically driven to form their secondary structure because it shields their 
hydrophobic residues from the aqueous environment (Crick 1953).  When in an organic 
solvent, however it is the hydrophilic and charged residues that are incompatible and this 
could drive the loss of the secondary structure.  The precipitation procedure would then 
pellet the nanoparticles, and resuspension in SDS would mean the coiled-coils would not 
have a chance to reform.   
Accordingly, the protein in all supernatant samples was precipitated using the 
methanol-chloroform precipitation method.  Pellet samples were resuspended in sample 
buffer.  This did allow nanoparticle bands to be seen, but it is worth noting that the 
presence of a small amount of dye at the top of the resolving gel indicates that not all of 
the nanoparticles were denatured by this method.  This can be seen in Figure 3.6 where the 
density of nanoparticle bands visible in the gel is less consistent than the density visible 
for either desmin or αB-crystallin.  Consequently, while an approximate ratio of the 
amounts of nanoparticles in the pellet and supernatant can be determined, accuracy is 
lacked.  However, this does not affect the chaperone assays, where it is the proportions of 
desmin and not of chaperone that are examined.  It is also worth noting that no trimer band 
was seen.  This is in contrast to what was seen earlier (section 3.1.Bioengineering, 
expression and purification of the nanoparticle peptides), when trimers, as well as 
monomers were seen pre-assembly.  This suggests that the suspension in SDS prevented 
any secondary structure from forming.       
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The samples also underwent centrifugation at high speed in order to establish 
chaperone binding to the desmin filaments (Figure 3.5).  This speed causes all of the 
desmin to be drawn into the pellet, regardless of whether the filaments are interacting or 
not.  Any protein that is bound to the filaments will therefore also be drawn into the pellet; 
hence, the more chaperone present in the pellet, the more has bound to desmin.   
All of the samples were also examined using TEM (Figure 3.8).  This was to see 
whether the desmin had formed filaments, and to examine their morphology.  It should be 
noted that the TEM images do not give a reliable indication of aggregation, as images 
were selected that best showed the morphology of the filaments, and not the aggregates.  
Moreover, aggregated proteins tend to stain badly or break through the carbon during 
sample preparation and so often cannot be seen well.  TEM can, in addition, give some 
indication of the level of chaperone binding. 
The results of the high and low speed centrifugations are shown in the bar chart in 
Figure 3.7.  At 22°C there was very little aggregation of desmin on its own, as shown by 
the red bar: only about 10% of the desmin was present in the pellet.  This was as expected, 
but indicates there was nothing to chaperone; so it is unsurprising that the corresponding 
bars for αB-crystallin and nanoparticles are of the same height.  The TEM images (Figure 
3.8: G, J, M) show that for all three samples long, regular filaments were formed and so 
aggregation seems not to be occurring.  At 37°C, however, about 60% of the desmin was 
present in the pellet, clearly showing that temperature was sufficient to cause the filaments 
to interact with each other and to aggregate, even though this aggregation is not apparent 
in the TEM image (Figure 3.8, H), for reasons discussed previously.  What the image does 
show, however, is that the desmin formed normal filaments, and hence that it was the heat 
causing their aggregation and nothing else.  The αB-crystallin chaperoned the aggregation 
to an extent, with about 40% of the desmin left in the pellet.  The nanoparticles, however, 
again chaperoned to an incredible extent, leaving less than 10% of the desmin in the 
pellet: the desmin was almost completely chaperoned by them.  They therefore, again, 
chaperoned at a much higher level then the sHSP. 
What is even more impressive, though, is the result at 44°C.  This high 
temperature caused 75% of the desmin to be brought into the pellet.  Thermal stress at this 
level is too great for αB-crystallin, and consequently no chaperoning was seen.  The  
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Figure 3.9 TEM images of the desmin assembly chaperone assay 
Proteins were stained with 1% uranyl acetate and photographed at 80000x magnification.  
Images chosen are, where possible, representative of the filaments seen in the sample.  
The assay was undertaken to determine the effects of the two protein chaperones on 
desmin filament aggregation at three temperatures, 22°C, 37°C and 44°C.  Samples 
containing only αB-crystallin, nanoparticles or desmin were used as controls. 
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nanoparticles, however, still managed to chaperone the filaments, so that only 20% 
were aggregated enough to be in the pellet.  For a temperature at which the natural 
chaperone had no effect at all, this really is a very exciting result.   
Although the TEM images are not used for determining aggregation, what was 
telling was the ease of taking the 44°C image for the sample of nanoparticles with desmin 
(Figure 3.8, O) compared to desmin alone and with αB-crystallin.  There were no fewer 
normal filaments seen on the grid than at lower temperatures.  For desmin and desmin 
with αB-crystallin, though, it was difficult to find filaments on the grid that were not in 
aggregates (Figure 3.8, I and L).  This is testament to the level of aggregation in these 
samples, and to the lack of it in the presence of nanoparticles.   
The TEM was also used to ensure that the structures of neither of the protein 
chaperones were affected by the heat, which could be cause of a lack of chaperoning.  
However, the structures of both seem consistent throughout (Figure 3.8, A-F). 
The high speed centrifugation (Figure 3.7, blue bars) was used to determine 
protein binding: the more of the chaperone that is present in the pellet, the more binding 
has occurred.  For αB-crystallin with desmin, a small amount of temperature dependent 
binding is seen, as compared to αB-crystallin by itself, where, as expected, there is very 
little in the pellet.  This is presumably because as the desmin is put under more thermal 
stress and so aggregates more, the αB-crystallin tries harder to chaperone it.  These results 
are mirrored in the TEM images (Figure 3.8): at 22°C (J) binding cannot be seen, whereas 
at 37°C (K) and 44°C (L) it can.   
 The binding of the nanoparticles to desmin, however, seems to be temperature 
independent: between 35%-45% consistently remained in the pellet.  Again, this result is 
mirrored in the TEM images: a large amount of nanoparticle binding is seen, regardless of 
the temperature (M, N, O).  This binding reaction seems to be independent of 
chaperoning, as binding occurs when chaperoning is not needed.  Furthermore, as the level 
of chaperoning increasing, the rate of binding stays the same.  Although 35%-45% does 
not seem to indicate a high level of binding, its temperature independency implies that the 
nanoparticles could be binding to the desmin at capacity.  This could be investigated by 
using a smaller concentration of nanoparticles relative to desmin.  
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4. Discussion 
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This project produced very exciting results: a new nanoparticle chaperone was found with 
remarkable chaperone efficiency and an activity range greater than any other published so 
far (see section 4.4. Nanoparticle chaperones).  These results will be interpreted in terms 
of the extent of the chaperone function that was found compared to that of αB-crystallin 
and the possible mechanism of this chaperone action.  The second objective of this project 
was to improve the chaperone function of the nanoparticles with regions of αB-crystallin.  
This part was unsuccessful, and the reason for this will be investigated.  These 
nanoparticles are not the first to be found to have chaperone activity; they will be put into 
the wider context of the field of nanoparticle chaperones and compared to those already in 
existence.  Lastly, the potential implications of this work will be discussed, as well as 
suggestions for future work that could be done on this project.  
 
 
4.1. Chaperone function of ‘empty’ nanoparticles 
 
As predicted (see below), the nanoparticles used in this project showed the ability to 
function as a protein chaperone.  The job of a protein chaperone is to prevent the 
aggregation of other proteins (section 1.2. Protein chaperones).  Protein aggregation does 
not happen to properly folded proteins, it occurs when proteins are unfolded, misfolded or 
denatured (non-native), as this allows their hydrophobic regions to be exposed; they 
should be on the inside of the protein.   However, when exposed, they bind to hydrophobic 
regions on other non-native proteins in an effort to avoid the solvent of the cell, and thus 
aggregation occurs.  Protein chaperones prevent this aggregation by binding to the 
hydrophobic areas with their own hydrophobic domains, and so shielding them from 
binding to other non-native proteins.  They either actively refold them with the aid of ATP 
(the chaperonins, HSP70, HSP90), or protect them until they can be refolded (the sHSPs); 
these are holdases.        
 The nanoparticles were predicted to function as protein chaperones because of 
their possible surface properties (see section 1.3.1. The Burkhard nanoparticles as 
chaperones).  They were designed to efficiently self-assemble by the use of coiled-coils; 
each monomer consists of a pentameric coiled-coil region and trimeric coiled-coil region, 
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and when in the right conditions these oligomerise to form a 60-mer (Raman, Machaidze 
et al. 2006).  These coiled-coils are stabilised by hydrophobic interactions (Burkhard, 
Stetefeld et al. 2001) and both contain other hydrophobic features: the pentameric coiled-
coil contains a long hydrophobic indent (Malashkevich, Kammerer et al. 1996), whilst the 
trimeric coiled-coil has a hydrophobic seam (Burkhard, Meier et al. 2000) (Raman, 
Machaidze et al. 2006).  Furthermore, their surface displayed proline-rich peptides (Figure 
1.1D), which will lack secondary structure, as well as being neural; characteristics shared 
with the αB-crystallin C-terminal tails.  Taken together, these features lead to our 
hypothesis that the nanoparticles could be able to act as protein chaperones. 
 This hypothesis was proved correct: the nanoparticles successfully chaperoned all 
three of the substrates used (section 3.3. Chaperone assays).  However, they not only 
chaperoned the substrates, they chaperoned them to a remarkable extent, performing much 
better than the αB-crystallin control that was used.  Their ability to chaperone aggregating 
proteins also stretched further than αB-crystallin in three directions.  Firstly, they could 
still perform as a chaperone far beyond the minimum concentration of αB-crystallin 
needed for effective chaperoning.  Reducing the concentration ratio of just 1:20 
nanoparticle:citrate synthase only slightly affected the chaperone function, whereas doing 
the same to αB-crystallin removed all chaperone ability (Figure 3.3); this demonstrates a 
very efficient chaperone mechanism.  It is probable that this efficiency is due to the 
symmetry of the nanoparticle.  The surface hydrophobic regions that are likely to be 
responsible for the chaperone affect will be repeated 60 times on each particle, as the 
nanoparticles are made of 60 identical monomers.  This would therefore create a very 
efficient chaperone.  
Secondly, their chaperoning was not impaired by increased thermal stress.  αB-
crystallin could chaperone desmin aggregation at 37°C, but by 44°C the aggregation was 
too great, and no chaperoning was seen (Figure 3.7).  The nanoparticles, however, 
chaperoned the filaments at 44°C to the same extent as 37°C, again, showing a high 
chaperoning efficiency.  The temperature independence of the interactions between the 
nanoparticles and desmin was striking.  At all three temperatures used (22°C, 37°C and 
44°C) the low speed sedimentation assay indicated the nanoparticles were causing similar 
levels of filament-filament interactions, despite the differences seen for desmin alone.  
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This strange behaviour could be an insight into just how powerful these nanoparticles are; 
desmin aggregation caused by 44°C does not seem to present a problem for them, 
therefore they could perhaps chaperone a much higher level of aggregation.  This could be 
tested by repeating these experiments at higher temperatures, or with a smaller 
concentration of nanoparticle relative to desmin.   
Likewise, the high speed assay showed the same level of nanoparticle binding at 
all three temperatures, when more binding at a higher temperature would be expected.  
This could imply saturated binding at 22°C, which therefore would be very efficient 
substrate binding.     
Thirdly, they have a much wider range of activity than αB-crystallin.  They were 
effective from 22°C up to 70°C.  This high temperature did not appear to effect the 
chaperoning of γ-crystallin; they still maintained almost complete chaperoning (Figure 
3.4).  This is a temperature at which most proteins would be denatured and lose activity, 
and so the fact that it has no effect on the activity of the nanoparticles is very impressive; 
it would be interesting to investigate just how big this range of activity is.  αB-crystallin, 
however, has a much smaller activity range: 70°C would cause denaturing and loss of 
activity, and so clearly the nanoparticles out-perform αB-crystallin in this area. 
 
 
4.2. Chaperone mechanism of ‘empty’ nanoparticles 
 
As previously mentioned, there are four main mechanisms of chaperone action seen in 
mammal cells (section 1.2. Protein chaperones).  The first is that of the chaperonins: the 
substrate binds to a hydrophobic active site within chamber, which subsequently 
undergoes a conformational change and causes the non-native protein to be refolded.  
Alternatively, HSP70 binds, with the aid of a co-chaperone, to a hydrophobic site on a 
nascent peptide and consequently causes the protein to fold.  Similarly, HSP90 facilities a 
co-chaperone to bind to the peptide, but then uses a ‘lid’ closure to enable refolding.  
Lastly, the sHSPs simply play a protective role by binding to the substrate until it can be 
passed on to be refolded.  The first three of these mechanisms utilise ATP to refold their 
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client protein, whereas the sHSPs differ, as they do not require ATP, but they are also not 
able to refold non-native peptides, and thus classed as holdases.   
The nanoparticles used do not require ATP to function and show no evidence of 
being capable of refolding peptides (although this has not been tested); therefore it is 
likely that they are also holdases, and their mechanism of action most resembles that of 
the sHSPs.  As already mentioned (section 1.3.1. The Burkhard nanoparticles as 
chaperones), they also show a structural similarity to the sHSPS:  they are both spheres 
comprised of subunits, although the sHSP subunit is a dimer while the nanoparticle 
subunit is a trimer and/or a pentamer, as the monomers were designed with both trimeric 
and pentameric coiled-coils . 
The mechanism of the sHSP chaperone function is not yet fully understood 
(section 1.2.4.2. The chaperone mechanism - αB-crystallin), although it is widely thought 
that substrate binding involves either subunit exchange, dissociation, conformational 
change or a mixture of the three, perhaps requiring activation (Haslbeck, Franzmann et al. 
2005).  It is known, however, that sHSP oligomers are dynamic, and thus constantly 
exchange subunits (Aquilina, Benesch et al. 2005), and SPR data has shown that increased 
subunit exchange leads to increased chaperoning (Liu, Ghosh et al. 2006).  Conversely, 
however, a crosslinking study prevented subunit exchange did not prevent chaperone 
activity (Franzmann, Wuhr et al. 2005); therefore different sHSPs may use different 
chaperoning mechanisms.   
 It is unlikely that the nanoparticles use subunit exchange or dissociation for their 
mechanism of chaperone activity.  This conclusion comes from their inability to be 
denatured by the process of boiling in SDS for running on a gel (section 3.2.1. Assembly 
of ‘empty nanoparticle’).  It suggests that the trimeric coiled-coils holding the subunits 
together are very strong, and so it seems unlikely that the subunits are dynamic.  What 
seems more probable is that their chaperoning regions are constantly displayed on their 
surface and no activation is required to induce the chaperone activity.  If activation was 
required for sHSP chaperoning and not for nanoparticle chaperoning, it could partly 
explain the nanoparticles’ more efficient chaperoning ability.  
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4.3. Chaperone function of nanoparticles displaying αB-crystallin regions 
 
A secondary hypothesis of this project was to investigate whether displaying regions of 
αB-crystallin known to be used in chaperoning improved their chaperone function.  
Unfortunately, however, testing this was impossible, as addition of these regions to the 
monomer resulted in precipitation and not nanoparticle formation.  Four different αB-
crystallin regions were used, but aggregation occurred in each case.  The reason for this 
could be that the regions of αB-crystallin that bind to substrates are also oligomerisation 
domains.  Consequently, all four of the regions used contained αB-crystallin 
oligomerisation domains (Figure 1.4), and so the αB-crystallin peptides bound to each 
other and thus prevented the formation of the nanoparticles.  αB-crystallin forms 
oligomers of different sizes, usually about 24-mers.  Here however, the monomers were 
expected to form 60-mers.  The oligomerisation domains therefore will be packed much 
more densely than would be seen for αB-crystallin, and this could have been another 
factor that led to their aggregation. 
 To solve this problem, regions of αB-crystallin could be used which do not contain 
oligomerisation domains.  These do tend to overlap with substrate binding domains, but 
from Figure 1.4 it can be seen that using amino acids 5-30 or 110-130 could solve this 
problem.  Alternatively, a high-throughput screening (HTS) technique could be employed 
in which many sequences are tried and tested.  Ones that did not lead to aggregation 
would then be tested for chaperone activity, and consequently the discovery of new 
substrate binding sites which are not involved in oligomerisation may give an insight into 
αB-crystallin’s chaperone mechanism.       
 It is unlikely that if this was successful the nanoparticles would have improved 
chaperone function compared to the ‘empty’ nanoparticles because they appear to be a 
better chaperone than αB-crystallin itself.  However, it would be useful by enabling more 
to be learnt about αB-crystallin, and perhaps in the future replace defective αB-crystallin 
in vivo. 
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4.4. Nanoparticle chaperones  
 
This is not the first time that nanoparticles have been found to be good protein chaperones.  
They have several properties which lend themselves to this function, the most important 
being their relatively large surface area, which causes them to have good adsorption 
capabilities.  Therefore they are able to bind to other molecules, which could be non-
native proteins; thus being able to perform a holdase function (Fei and Perrett 2009).  
They also have the added advantage that their surfaces can usually be modified and so the 
surface properties can be optimised, potentially creating very efficient protein chaperones. 
 Because of these factors several different nanoparticles have been designed with the 
purpose of creating an effective protein chaperone (section 1.2.5. Nanoparticle 
chaperones).     
 Some of these have metal cores. (De and Rotello 2008) De et al (De and Rotello 
2008) created gold nanoparticles functionalised with dicarboxylate sidechains, which 
could chaperone three clients by using electrostatic interactions.  In a similar mechanism, 
titanium oxide nanoparticles were effective on three substrates (Raghava, Singh et al. 
2009).  Magnetic ion nanoparticles have also been functionalised to have a chaperone 
function, although these have only been tested on one substrate (Badruddoza, Hidajat et al. 
2010).   All these nanoparticles not only prevented their clients from aggregating, but 
allow them to revert back to an active form.  This is something that has not yet been tested 
with these nanoparticles; it would be exciting to see if they have the potential to restore 
enzymatic activity to their substrates. 
 Other chaperoning nanoparticles include micelles formed from amphiphillic 
polymers, which have a hydrophobic surface (Cavalieri, Chiessi et al. 2007), and a 
hydrogel of cholesteryl-group-bearing pullulan (CHP) (Nomura, Sasaki et al. 2005), both 
which have been found to have refolding ability on denatured carbonic anhydrase B 
(CAB), but with no results from further substrates yet. 
 The nanoparticles that have been made and tested in this project excel from the 
ones that have been published so far in their range of activity.  The three chaperone assays 
put to them were all very different and highlighted different properties of their 
chaperoning.  The tests done on the nanoparticles previously published so far have not 
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done this; even when different substrates were used, they were used under the same 
conditions, and highlighted their ability to aid the refolding of non-native proteins.   
 These peptide nanoparticles however are capable of more than that.  In the citrate 
synthase assay (Figure 3.3) they showed that they are capable of complete chaperoning of 
a denatured substrate, at relatively normal conditions.  This is comparable to the studies 
done on other nanoparticle chaperones.  They were then tested at an extreme temperature 
in the γ-crystallin assay; where at 70ºC their ability to chaperone did not seem to be 
affected.  This was a very impressive display of their robust nature.  Lastly, they were 
successfully used in the desmin assay.  This assay tested a completely different type of 
chaperoning: instead of preventing the aggregation of non-native proteins, they prevented 
filament-filament interactions from occurring.  These filaments were not non-native 
proteins, and so clearly a different chaperone mechanism is required for this assay. 
 These nanoparticles are also the only protein nanoparticle chaperones.  This makes 
them very easy to synthesise, and also makes them safer than the metal-based 
nanoparticles when considering potentially using them for applications in the body.  They 
are therefore a very attractive alternative to the nanoparticle chaperones that have 
previously been published. 
One more interesting feature of these nanoparticles is that they are the first that 
have been designed for an ulterior function yet have been discovered to have chaperone 
function.  All of the others, therefore, have been designed with known principles of 
chaperoning in mind.  This accidental property is thus very exciting; it could give a great 
new insight into the chaperone mechanism and so further investigation could lead to 
important findings.    
  
 
4.5. Potential of this technology 
 
Protein aggregation in the body is involved in many human diseases; known as protein 
aggregation diseases, examples of which include cataract, type 2 diabetes and 
neurodegenerative diseases such as Huntington’s disease, Parkinson’s disease and 
Alzheimer’s disease.  These diseases generally involve a complex, multistep process in 
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which protein aggregates become either ordered fibrils (amyloid) or amorphous deposites 
(Figure 4.1).  These cannot be broken down, and are deposited; the composition and 
location of the deposits determines the disease (Bartolini and Andrisano 2010) (Dobson 
2003).  Consequently, there is great importance in the current research that is trying to 
find a way to prevent these aggregates from forming.  Unfortunately, it is not simply a 
case of stopping proteins from aggregating; the proteins implicated in these diseases are 
usually defective in some way: either as the result of mutation or old age, and so simply 
chaperoning the protein does not solve the problem.  However producing such effective 
protein chaperones as these gives a platform from which more research could proceed to 
perhaps in the future find a way to control production of these deposits.  Furthermore, 
introducing chaperones in the early steps of these diseases could potentially slow down 
the progression of the diseases; in the case of aggregation diseases related to old age, this 
would greatly increase the quality of life for both the suffers and their carers.  Using 
nanoparticle chaperones for this purpose instead of traditional drugs is convenient as their 
small size allows them to pass through the blood brain barrier (see section 1.1.1. Drug 
delivery), which is required when treating neurodegenerative diseases (Chopra, Gulati et 
al. 2008).   
These nanoparticles have not yet been tested on amyloid fibrils however; there 
have been mixed results on the effects that nanoparticles can have on amyloid fibrils.  
Some nanoparticles have been found to retard the rate of fibrillogensis (Cabaleiro-Lago, 
Quinlan-Pluck et al. 2008) (Pai, Rubinstein et al. 2006), whereas other have been found 
actually increase it by accelerating the nucleation step, the rate limiting step (Wu, Sun et 
al. 2008) (Linse, Cabaleiro-Lago et al. 2007).  This happens because the peptides are 
adsorbed to the nanoparticles’ surface, making the peptide concentration very high and so 
promoting them to interact.  However, it is also this adsorption that can reduce the 
fibrillogensis rate by blocking the active sites of the peptides.  Therefore, further research 
needs to be carried out on these nanoparticles, as to whether they are effective on amyloid 
fibrils. 
Whilst much is known about protein chaperones, there is still a great deal that is 
unknown.  As mentioned previously, there are no synthetic nanoparticle chaperones that 
are similar to these; their peptide composition makes them unique.  Therefore, 
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investigation into their exact method of aggregation inhibition could provide insights into 
the nature of the process by which protein aggregation occurs, particularly how amyloid 
fibrils form; knowledge which would indirectly aid the fight against protein aggregation 
diseases (Bartolini and Andrisano 2010). 
The protein chaperone properties of these nanoparticles could also have a 
commercial application within the field of biotechnology.  One example of how this 
would be used is as follows.  As demonstrated in this project, bacteria are often used to 
overexpress recombinant proteins, yet up to 95% of the produced protein can form 
insoluble aggregates.  This is usually dealt with by solubilising in a denaturant such as  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 The protein aggregation 
process. 
The steps involves in the development 
of protein into toxic deposits.  Taken 
from (Bartolini and Andrisano 2010). 
 62 
urea; alternatively aggregation could be prevented by using an artificial chaperone 
(Cavalieri, Chiessi et al. 2007).  As they are robust, peptide-based, cheap and most 
importantly excellent chaperones, these nanoparticles would be perfect for such an 
application. 
If this project were to continue, there is further work that could be done.  More 
structural characterisation of the nanoparticles produced could be carried out to investigate  
their exact size and number of monomers.  They could also undergo a heat denaturisation 
experiment, where they would be heated until they began to denature.  This would give 
further information into how big their thermal range of activity is.  Their exact chaperone 
mechanism could be determined and used in the production of chaperones in the future.   
 Research could also be done into their substrate range.  It would be easy to test 
them on other general chaperone substrates such as insulin, CAB, papain and lysozyme.  
Their refolding potential on these substrates could also be investigated.  They then could 
be tested on substrates that would require a different chaperone mechanism, such as pre-
fibrillar proteins, as already mentioned.    
 The results from the desmin chaperone assay were very exciting as to the 
chaperone potential of these nanoparticles.  More could be learnt from the assay, by 
lowering the relative nanoparticle concentration by increasing the temperature to push the 
nanoparticles further. 
 Lastly, as again already discussed, more work could be done on creating 
nanoparticles with αB-crystallin fragments displayed on their surface to investigate the 
effect that this could have and if it is possible to create an αB-crystallin ‘super-chaperone’.   
 
 
4.6. Conclusions 
 
This project has uncovered a nanoparticle chaperone with great potential.  It is very quick 
and easy to produce, adaptable by the modification of its monomers, and very robust.  
Most importantly however, it chaperones non-native proteins to a very high extent and has 
a wide activity range.  Further research must now be carried out to determine the exact 
chaperone mechanism and thus to discover why the chaperoning is so remarkable.  Work 
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must also be done to establish more substrates that these nanoparticles are effective on, 
especially pre-fibrillar proteins, in the hope that they can one day help to deal with protein 
aggregation diseases.   
The project has made a very exciting discovery, and the implications of these 
results will be huge.     
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